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A B S T R A C T
Background
Herbal medicine interventions have been identified as having potential benefit in the treatment of rheumatoid arthritis (RA).
Objectives
To update an existing systematic (Cochrane) review of herbal therapies in RA.
Search methods
We searched electronic databases Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE,
AMED, CINAHL, Web of Science, Dissertation Abstracts (1996 to 2009), unrestricted by language, and the WHO International Clinical Trials
Registry Platform in October 2010.
Selection criteria
Randomised controlled trials of herbal interventions compared with placebo or active controls in RA.
Data collection and analysis
Two authors selected trials for inclusion, assessed risk of bias and extracted data.
Main results
Twelve new studies were added to the update, a total of 22 studies were included.
Evidence from seven studies indicate potential benefits of gamma linolenic acid (GLA) from evening primrose oil, borage seed oil, or black-
current seed oil, in terms of reduced pain intensity (mean difference (MD) -32.83 points, 95% confidence interval (CI) -56.25 to -9.42,100
point pain scale); improved disability (MD -15.75% 95% CI -27.06 to -4.44%); and an increase in adverse events (GLA 20% versus placebo
3%), that was not statistically different (relative risk 4.24, 95% CI 0.78 to 22.99).
Three studies compared Tripterygium wilfordii (thunder god vine) to placebo and one to sulfasalazine and indicated improvements in
some outcomes, but data could not be pooled due to differing interventions, comparisons and outcomes. One study reported serious
side effects with oral Tripterygium wilfordii Hook F. In the follow-up studies, all side effects were mild to moderate and resolved after the
intervention ceased. Two studies compared Phytodolor® N to placebo but poor reporting limited data extraction. The remaining studies
each considered differing herbal interventions.
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Authors' conclusions
Several herbal interventions are inadequately justified by single studies or non-comparable studies in the treatment of rheumatoid arthri-
tis. There is moderate evidence that oils containing GLA (evening primrose, borage, or blackcurrant seed oil) afford some benefit in reliev-
ing symptoms for RA, while evidence for Phytodolor® N is less convincing.Tripterygium wilfordii products may reduce some RA symptoms,
however, oral use may be associated with several side effects. Many trials of herbal therapies are hampered by research design flaws and
inadequate reporting. Further investigation of each herbal therapy is warranted, particularly via well designed, fully powered, confirma-
tory clinical trials that use American College of Rheumatology improvement criteria to measure outcomes and report results according
to CONSORT guidelines.
P L A I N   L A N G U A G E   S U M M A R Y
Herbal therapy for rheumatoid arthritis
This summary of a Cochrane review presents what we know from research about the effects of herbal therapy for rheumatoid arthritis (RA).
The review shows that in people with RA:
- Evening primrose oil, borage seed oil, or blackcurrent seed oil (containing gamma-linolenic acid (GLA)) probably improve pain; may
improve function; and probably does not increase adverse events (unwanted side effects).
- Tripterygium wilfordii Hook F may improve some symptoms of rheumatoid arthritis, and higher doses (180 mg - 350 mg daily) may be
more effective than lower doses (60 mg daily). There are some adverse events associated with Tripterygium wilfordii Hook F.
- We are uncertain of the effects of other herbal therapies because only single studies were available, or important features of RA, such as
changes in the number of swollen and tender joints, were not reported.
Often we do not have precise information about side effects and complications, particularly for rare but serious side effects. Possible side
effects associated with Triperygium wilfordii Hook F may include painful periods in women, decreased fertility in men, insufficient urine
excretion, and increased rate of infections. Possible side effects associated with GLA sourced from evening primrose oil include headache,
nausea, and diarrhoea, and rare complications include allergy and seizures.
What is rheumatoid arthritis and what is herbal therapy?
When you have RA, your immune system, which normally fights infection, attacks the lining of your joints. This makes your joints swollen,
sti@ and painful. The small joints of your hands and feet are usually affected first. There is no cure for rheumatoid arthritis at present, so
treatments are used to relieve pain and stiffness and improve your ability to move.
Herbal interventions are defined as any plant preparation (whole, powder, extract, standardised mixture) used for medicinal purposes.
Historically, many herbal therapies have been used to treat RA. Like conventional non-herbal drugs, many herbal therapies are believed
to act by blocking the activity of these immune cells and substances and reducing inflammation in the joints, and some people believe
they have fewer side effects.
Best estimate of what happens to people with rheumatoid arthritis:
Pain (higher scores mean worse or more severe pain):
-People who took eveing primrose oil, primrose oil, borage seed oil, or blackcurrent seed oil (wih the active ingredient GLA) rated their
pain to be 33 points lower (9 to 56 points lower) on a scale of 0 to 100 after 6 months of treatment (33% absolute improvement).
-People who took placebo rated their pain to be 19 points lower after treatment.
Physical function (higher score means greater disability):
-People who took GLA rated their disability 16% better.
-People who placebo rated their disability 5% better.
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Summary of findings for the main comparison.
Evening primrose oil, borage seed oil, blackcurrent seed oil (containing gamma-linolenic acid) for rheumatoid arthritis
Patient or population: patients with treating rheumatoid arthritis
Settings: community
Intervention: Evening primrose oil, borage seed oil, blackcurrent seed oil (with gamma-linolenic acid) versus placebo
Illustrative comparative risks* (95%
CI)
Outcomes
Assumed risk Corresponding risk
Relative ef-
fect 
(95% CI)
No of Partici-
pants 
(studies)
Quality of the
evidence 
(GRADE)
Comments
  Control Evening primrose
oil, borage seed
oil, blackcurrent
seed oil (with gam-
ma-linolenic acid)
versus placebo
       
ACR 50% improvement - not mea-
sured
See comment See comment Not estimable - See comment Not measured
Pain 
Visual Analogue Scale. Scale from: 0
to 100. 
(follow-up: 6 months)
The mean
pain in the
control
groups was 
60.6 points1
The mean Pain in the
intervention groups
was 
32.83 lower 
(56.25 to 9.42 lower)
  82 
(3)
⊕⊕⊕⊝ 
moderate2
Absolute risk difference 33 points
lower (9 to 56 points lower); rel-
ative % change 54% (15 to 92%);
NNTB 3 (2 to 12)3
Disability (HAQ score) 
percent change. Scale from: 0 to
100. 
(follow-up: 6 months)
The mean
disability
(haq score)
in the control
groups was 
42.5 4
The mean Disability
(HAQ score) in the in-
tervention groups was 
16 lower 
(27 to 4 lower)
  41 
(1)
⊕⊕⊝⊝ 
low2,5
Absolute risk difference 16% lower
(4 to 27% lower); relative % change
38% (9% to 64%); NNTB 3 (95% CI 2
to 11)
Medium risk populationParticipants (n) reported adverse
events 
(follow-up: 6 months) 39 per 1000 165 per 1000 
(30 to 897)
RR 4.24 
(0.78 to 22.99)
61 
(2)
⊕⊕⊕⊝ 
moderate2
Absolute risk difference 15% (0
to 30%); relative percent change
324% (-22% to 2199 %); NNT=n/a 3
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Change in radiographic progres-
sion - not measured
See comment See comment Not estimable - See comment Not measured
Achievement of low disease state
(DAS 28) - not measured
See comment See comment Not estimable - See comment Not measured
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidance 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate.
1 From Zurier 1996, mean (SD) pain at baseline in placebo = 60.6 (21.0)
2 Unclear if randomisation was concealed or outcome assessor blinded
3 NOTE: Number needed to treat (NNT)=n/a when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nnton-
line.net/visualrx/). NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office).
4 From Zurier 1996, mean (SD) HAQ score on 0-100 scale at baseline in placebo = 42.5 (11.25)
5 Results based on one small trial nly
 
 
Summary of findings 2.
Triptrygium wilfordii Hook F 360 mg versus placebo for Rheumatoid arthritis
Patient or population: patients with Rheumatoid arthritis
Settings: Community
Intervention: Triptrygium wilfordii Hook F 360 mg versus placebo
Illustrative comparative
risks* (95% CI)
Outcomes
Assumed risk Correspond-
ing risk
Relative effect 
(95% CI)
No of Partici-
pants 
(studies)
Quality of the
evidence 
(GRADE)
Comments
  Control Triptrygium
wilfordii
Hook F 360
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mg versus
placebo
Medium risk population1ACR 50% improvement 
(follow-up: 20 weeks)
1 per 1000 12 per 1000 
(1 to 193)
RR 11.92 
(0.73 to 193.38)
23 
(1)
⊕⊕⊝⊝ 
low2,3
Absolute risk difference = 45% (15% to
76%) increase; relative percent change
= 1090% (-27% to 19238%); NNTB n/a4
Change in pain - not measured See comment See comment Not estimable - See comment Not measured
HAQ disability score - not measured See comment See comment Not estimable - See comment Not measured
Medium risk populationParticipants (n) reported adverse
events 
(follow-up: 20 weeks) 333 per 1000 453 per 1000 
(163 to 1272)
RR 1.36 
(0.49 to 3.82)
23 
(1)
⊕⊕⊝⊝ 
low2,3
Absolute risk difference = 12% in-
crease (-28% to 52%); relative percent
change = 36% (-51% to 282%); NNTH =
n/a 
4
Change in radiographic progres-
sion - not measured
See comment See comment Not estimable - See comment Not measured
Achievement of low disease state
(DAS 28) - not measured
See comment See comment Not estimable - See comment Not measured
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidance 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate.
1 Only one study available, with control event rate of 0%; thus assumed 1% control event rate for purposes of calculations; control event rates for 5 trials in review (different
therapies) ranged from 0 to 35%
2 Unclear if randomisation was concealed
3 Results based on one small trial
4 NOTE: Number needed to treat (NNT)=n/a when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nnton-
line.net/visualrx/); or for single studies as 1/RD. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office)
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B A C K G R O U N D
Rheumatoid arthritis (RA) is a common, immune-mediated dis-
ease characterized by chronically progressive inflammation and
destruction of joints and associated structures as well as systemic
symptoms. Early diagnosis and advances in molecular biology have
led to improved therapy and better outcomes for patients, but the
disease still causes a significant burden of illness. Current therapy
has a goal of complete and long-lasting remission but, typically, on-
ly partial remission is achieved and frequent relapses or even non-
response are common (Tarner 2008). Because many antirheumatic
and immune-modulating drugs in current use are associated with
severe, possibly life-threatening, adverse effects (Tarner 2008) it is
understandable that many patients of rheumatologists use com-
plementary or alternative medicines (CAM) including herbal medi-
cines which they may believe to be safer (Boisset 1994; Buchbinder
2002; Cronan 1989).
Historically, there have been a variety of herbal medicines that have
been used in the treatment of rheumatological conditions, includ-
ing conditions resembling what we now know as RA. For example,
in Chinese medicine 'Lei Gong Teng' (thunder god vine or 'three-
wing nut') has been used for centuries to treat inflammatory tissue
swelling (MacPherson 1994), preparations of Salix species (Vlacho-
jannis 2009), devil's claw (Harpagophytum procumbens) (Chrubasik
2007a) and nettle (Urtica dioica) (Chrubasik 2007b) are popular an-
tirheumatic remedies in Europe, and Zingiber officinalis (Chrubasik
2005), Capsicum frutescens, Mentha piperita, Arnica montana, Cur-
cuma longa, Tanacetum parthenium, and Zingiber officinalis have
been reported as treatments for various types of pain including
joint pain (Chrubasik 2007a, ESCOP 2009).
Several novel therapeutic targets have been identified as involved
in the pathogenesis of RA. These include molecules that regulate
tumor necrosis factor (TNF) (eg: TNF-alpha converting enzyme),
the complex cytokine network (eg: IL-6, IL-15, IL-17) and several
adipokines. Strategies that aim at cellular targets of the disease in-
clude antibodies to CD20 or BLyS (also known as TNF ligand family
member 13b), which deplete or inhibit B cells, and approaches that
interfere with membrane-derived microparticles. Components of
subcellular pathways, which are predominantly upstream of the
central regulator of transcription nuclear factor kappaB, are also in-
volved, such as mitogen-activated protein kinases, Janus kinases,
signal transducer, activator of transcription proteins and suppres-
sors of cytokine signalling proteins (Tarner 2007). Non-herbal tradi-
tional disease modifying anti-rheumatic drugs, such as methotrex-
ate, may target several of the systems described above to reduce in-
flammation (Katchamart 2010). Similarly, several herbal medicinal
products may act as multi-component drugs at the molecular lev-
el, acting on several therapeutic targets simultaneously. The newer
biologic disease-modifying anti-rheumatic drugs target individual
components of these systems (Singh 2009).
Most of the herbal medicinal products used orally have a broad
mechanism of action, as shown by in vitro studies. We recently sum-
marized the in vitro studies for most of these herbal medicinal prod-
ucts (Cameron 2009). Herbal medicinal products may be more or
less involved in the inhibition of cyclo-oxygenase-1 or 2, lipoxyge-
nase and enzymes that participate in cartilage destruction, such as
elastase and hyaluronidase. The active principles may also inhibit
the release of pro-inflammatory cytokines and stimulate the pro-
duction of cytokines that inactivate enzymes, such as metallopro-
teinases (Cameron 2009). For most of the HMPs a radical scaveng-
ing effect was also demonstrated. Topical capsaicin has a differ-
ent mechanism of action. It stimulates the vanilloid receptors (De-
dov 2000), interferes with the synthesis, storage, transport and re-
lease of substance P (Buck 1986), inhibits the lipoxygenase (Flynn
1986) and reversibly destroys fine nerve endings (Nolano 1999). Al-
so, Uncaria tormentosa (cat's claw) and Tanacetum parthenium are
anti-inflammatory and antinociceptive as well as acting on 5-HT2
receptors (Jurgensen 2005; Mittra 2000). Therefore, it appears that
herbal medicines have some mechanisms of action that have rele-
vance to the pathogenesis and symptoms associated with rheuma-
toid arthritis.
O B J E C T I V E S
To update an existing Cochrane systematic review of the effective-
ness of herbal therapies in the treatment of rheumatoid arthritis
(RA) by adding data from relevant clinical trials published in the pe-
riod from 2000 to 2009.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled (placebo or active control) parallel and
crossover trials examining the effects of herbal interventions for
treating RA.
Types of participants
All persons diagnosed with RA according to American College of
Rheumatology (ACR) criteria (Arnett 1988). Studies with samples
defined according to vague descriptions (eg: 'joint pain') were not
considered.
Types of interventions
Any form of herbal intervention compared with an inert (placebo)
or active control, via any route of administration, was included.
Herbal therapy used in conjunction with other treatments or com-
bined with a non-herbal substance were also included if the ef-
fect of the non-herbal intervention was (a) consistent among all
groups, and (b) quantifiable. Herbal interventions included any
plant preparation (whole, powder, extract, standardised mixture)
but excluded homeopathy, aromatherapy or any preparation of
synthetic origin.
Types of outcome measures
As far as possible, we extracted data for these main outcomes as
recommended by the Cochrane Musculoskeletal Group: disease ac-
tivity as measured by proportion with American College of Rheuma-
tology 50% improvement (ACR50 responders), or ACR20 respon-
ders if reported; reduction in pain; physical function as measured
by the Health Assessment Questionnaire (HAQ); achievement of
low disease state as measured by the Disease Activity Score (DAS);
change in radiographic progression; number of participants with
any adverse event, or number of adverse events.
Other outcomes included: proportion of ACR20 responders,
swollen joint count, tender joint count, measures of joint stiffness,
grip strength, withdrawals due to adverse events.
Herbal therapy for treating rheumatoid arthritis (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
6
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Search methods for identification of studies
For this review update we searched the following electronic data-
bases (from the date of the last search in the previously published
version of the review to May 21st, 2009):
1. Cochrane Central Register of Controlled Trials (CENTRAL) (The
Cochrane Library Issue 1, 2009);
2. MEDLINE via Ovid (2000 to May Week 2 2009);
3. EMBASE via Ovid (2000 to May 2009);
4. AMED via Ovid (1985 to May 2009);
5. CINAHL via Ovid (2000 to Week 5 2008), via EBSCOHost (2008 to
May 2009);
6. Dissertation Abstracts (May 2009);
7. Web of Science (May 2009).
Thesaurus and free text searches were performed, appropriate to
each database, to combine terms describing RA and terms describ-
ing herbal medicine. No methodological filter was applied and the
search was not limited by language.
The full search strategies for each database are outlined in Appen-
dix 1.
We searched the WHO International Clinical Trials Registry Plat-
form in October 2010 (http://www.who.int/ictrp/en/) for ongoing
and unpublished trials.
Data collection and analysis
Selection of studies
Because of the large number of studies included in this update
and the inclusion of studies in languages other than English, all re-
view authors and some assistants (authors of the previous review,
and a colleague from the German Cochrane Centre) contributed to
eligibility decisions and data extraction. The contributions of au-
thors and assistants are detailed at the end of this review. All titles
and abstracts identified from the electronic databases and other
searches were independently examined by at least two review au-
thors. The full manuscript was retrieved for each record that had
the possibility of meeting the review criteria. At least two authors
independently assessed eligibility of each retrieved study for re-
view according to the inclusion criteria. Data were extracted from
each eligible study by two review authors or assistants acting inde-
pendently.
Where a study was defined as a crossover trial, data were extracted
only up to the point of crossover in order that these data could be
compared with those derived from parallel group trials. Where an
outcome was reported using two outcome measures (eg, pain on a
continuous 100 point VAS scale and pain on a categorical scale of
0 to 4 points), data were displayed preferentially using the contin-
uous scale. Results are reported for the categorical scale out of in-
terest.
Assessment of risk of bias
Three review authors (MC, SC, JG) assessed the risk of bias of the in-
cluded trials against key criteria: random sequence generation; al-
location concealment; blinding of participants, personnel and out-
come assessors; incomplete outcome data; selective outcome re-
porting; and other sources of bias, in accordance with methods rec-
ommended by The Cochrane Collaboration (Higgins 2008). Each
criterion was judged explicitly as: A = Yes, low risk of bias; B = No,
high risk of bias; C = Unclear, either lack of information or uncer-
tainty over the potential for bias. Potential disagreements were dis-
cussed and resolved by referring to the original protocol and, if nec-
essary, arbitration by a member(s) of the steering group.
Analysis
Descriptive results were reported for all included studies. Studies
with the same comparator were pooled in meta-analyses, and a
random effects model applied. For dichotomous outcomes, odds
ratios or relative risks were calculated. For continuous outcomes, a
mean difference (MD) was calculated, and confidence intervals (CI)
reported at 95%. The Chi2 test and I2 statistic of heterogeneity were
conducted. Threshold values (P and I2) for heterogeneity were not
determined a priori; rather heterogeneity was reported using both
Chi2 and I2 statistics, with I2 of 30% to 60% considered to represent
moderate heterogeneity, and I2 of more than 60% as substantial
heterogeneity. This categorical classification was consistent with
the Chi2 statistic analyses if P = 0.10 was accepted as the arbiter of
significance. Reasons for heterogeneity were explored by reviewing
study designs and results. I2 ≥ 80% was considered to represent un-
acceptable heterogeneity, indicating that the studies could not be
rationally pooled. Studies that reported pooled data were analysed
using the generic inverse variance method.
Summary of findings
Main results of the review are presented in the summary of find-
ings tables, including an overall grading of the evidence using the
GRADE approach (Schünemann 2008b) and a summary of the avail-
able data on the main outcomes, as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2008a). We present a summary of findings table gamma linolenic
acid 1400mg or greater versus placebo, and Triptrygium wilfordii
Hook F 360 mg versus placebo (there were insufficient outocme
data from single trials for the other interventions). We included
the outcomes recommended as by the Cochrane Musculoskeletal
Group for reviews of interventions for rheumatoid arthritis (disease
activity as measured by proportion with ACR50 improvement; re-
duction in pain; physical function as measured by HAQ; achievment
of low disease state as measured by DAS; change in radiographic
progression; number of participants with any adverse event). The
GRADE approach categorises the quality of evidence for as high,
moderate, low or very low as an indication of confidence in the re-
sults of studies and meta-analyses. For example, high quality evi-
dence is robust and further studies are very unlikely to change our
confidence in the estimate of effect; conversely, low quality evi-
dence is open to question and further research is very likely to have
an important impact on our confidence in the estimate of effect and
may change the estimate.
We also determined the absolute risk difference and relative per-
cent change and entered these into the comments column of the
'Summary of findings' table. For dichotomous data, the absolute
risk difference is calculated by using RevMan to generate the Risk
Difference analysis and then reporting the result as a percentage.
The relative percent change is calculated by finding the relative risk
(RR) from RevMan and then applying the formula RR-1 equals the
relative percent change. The number needed to treat (NNT) was
calculated for statistically significant outcomes from the control
group event rate (unless the population event rate was known) and
the relative risk using the Visual Rx NNT calculator (Cates 2004). For
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continuous outcomes, absolute risk difference was derived from
the mean difference (MD) generated in RevMan divided by scale of
the instrument; relative percent change was derived from MD divid-
ed by the basline mean of the control group; and NNT was calcu-
lated for statistically significant outcomes using the Wells calcula-
tor at the CMSG editorial office (www.cochranemsk.org). The Wells
calculator requires input of the minimally important clinical differ-
ence (MCID) for continuous outcomes: For pain we used an MCID of
15 out of 100 points, and for function, an MCID of 0.22 units on a 0
to 3 HAQ scale (or 7% on change scale) to estimate NNT.
R E S U L T S
Description of studies
See: tables 'Characteristics of included studies'.
From approximately 2500 citations, a total of 12 new studies, in-
cluding four studies published prior to 2000, were identified for in-
clusion in the updated review (Biegert 2004; Chopra 2000; Cibere
2003; Eberl 1988; Goldbach-Mansky 2009; Li 2007; McCarthy 1992;
Meier 1987; Mur 2002; Sandler 1998; Song 2007; Tao 2002). These
studies were added to 10 of the 11 studies included in the original
review (Belch 1988; Brzeski 1991; Deal 1991; Jantti 1989; Leventhal
1993; Leventhal 1994; Pattrick 1989; Tao 1989; Watson 1993; Zuri-
er 1996). One trial was identified via the search of the WHO Clinical
Trial Registry (Shamsi 2009), however we did not find any published
results from this trial.
One study included in the original review recruited participants
with any form of arthritic disease (Mills 1996). This study was ex-
cluded from this update because data for the subgroup of partic-
ipants with RA could not be distinguished from the overall data
reported. Other reasons for excluding studies were: (a) not a ran-
domised controlled trial, (b) discussion paper, (c) full study details
not available, (d) unable to identify the herbal components of the
intervention, (e) case series, (f) review paper, (g) inappropriate sta-
tistical analysis, or (h) duplicate publication. See: tables 'Charac-
teristics of excluded studies'.
Twenty of the studies were of parallel design (Belch 1988; Biegert
2004; Brzeski 1991; Chopra 2000; Cibere 2003; Deal 1991; Eberl 1988;
Goldbach-Mansky 2009; Li 2007; Jantti 1989; Leventhal 1993; Lev-
enthal 1994; McCarthy 1992; Meier 1987; Mur 2002; Pattrick 1989;
Sandler 1998; Song 2007; Tao 2002; Watson 1993), one used a
crossover design (Tao 1989) and one had a partial crossover design
(Zurier 1996).
The 22 studies covered 13 herbal interventions, four being combi-
nation products. Herbal monopreparations included borage seed
oil (two studies), blackcurrant seed oil (two studies) and evening
primrose oil (three studies) as plant sources of gamma linolenic
acid; Tanacetum parthenium (feverfew; one study); Uncaria tomen-
tosa (cat's claw; one study); Salix cortex (willow bark); Boswellia ser-
rata; Tripterygium wilfordii (thunder god vine) (two studies) in topi-
cal and oral preparations; and topical capsaicin (one study). Herbal
mixtures included the Ayurvedic formula RA-1 (one study); SKI306X
(one study); Ganoderma lucidum, a mushroom given together with
San Miao San consisting of Rhizoma atractylodis, Cotex phellodendri
and Radix achyranthes bidentatae (one study); and finally Phytodo-
lor® N consisting of Populus tremula, Fraxinus excelsior and Solida-
go virgaurea (two studies).
One study (Belch 1988) included three parallel arms comparing
evening primrose oil, a mixture of evening primrose oil and fish oil,
and placebo, but only the evening primrose oil and placebo arms
were considered in this review. Two studies included data on peo-
ple with osteoarthritis (OA) as well as RA. These data were present-
ed separately in one study (Deal 1991) but were not presented for
the RA subgroup in the other (Mills 1996).
Seven of the studies investigated the effects of plant sourced gam-
ma-linolenic acid (GLA) on a total of 286 participants. Sources of
GLA were evening primrose oil (EPO) (Belch 1988; Brzeski 1991;
Jantti 1989), blackcurrant seed oil (Leventhal 1994; Watson 1993)
and borage seed oil (Leventhal 1993; Zurier 1996). Placebo oils used
in the GLA studies included olive oil (Brzeski 1991; Jantti 1989), sun-
flower oil (Watson 1993; Zurier 1996), liquid paraffin (Belch 1988),
cottonseed oil (Leventhal 1993) and soybean oil (Leventhal 1994).
The remaining studies included in the review reported the effects
of oral interventions of SKI306X on 183 participants (Song 2007),
RA-1 on 182 participants (Chopra 2000), Tripterygium wilfordii Hook
F on 226 participants (Goldbach-Mansky 2009; Tao 1989; Tao 2002),
Boswellia serrata on 78 participants (Sandler 1998), Phytodolor® N
on 47 participants (Eberl 1988; Meier 1987), feverfew on 41 partici-
pants (Pattrick 1989), cat's claw on 40 participants (Mur 2002), wil-
low bark on 26 participants (Biegert 2004), Ganoderma lucidum to-
gether with San Miao San on 65 participants (Li 2007) and the ef-
fects of topical applications of Tripterygium wilfordii on 61 partic-
ipants (Cibere 2003) and capsaicin on 38 participants (Deal 1991;
McCarthy 1992).
Overall, the studies reported a wide variety of clinical outcomes
with some studies also reporting biochemical outcomes (Belch
1988; Goldbach-Mansky 2009; Jantti 1989; Leventhal 1993; Leven-
thal 1994; Li 2007; Pattrick 1989; Sandler 1998; Tao 1989; Watson
1993). Only clinical outcomes were considered in this review.
Risk of bias in included studies
See: tables 'Risk of bias'.
The risk of bias of each study was assessed independently by two
review authors according to the criteria described in the methods
(Higgins 2008; Schünemann 2008a; Schünemann 2008b). Quality of
the included studies was variable and should be taken into account
when interpreting the results of this review. In general, method-
ological quality of the new studies was superior to that of the old-
er studies, suggesting that quality of research design and reporting
has improved since 2000 (Biegert 2004; Chopra 2000; Li 2007; Song
2007).
A total of three studies adequately met all six validity criteria and
thus were at minimal risk of bias (Biegert 2004; Chopra 2000; Song
2007). In six studies the method of randomisation was not de-
scribed (Belch 1988; Jantti 1989; Mur 2002; Pattrick 1989; Sandler
1998; Tao 2002), in two studies the method of blinding was not
described (Goldbach-Mansky 2009; Meier 1987) and in one study
numbers and reasons for withdrawals were not reported (Cibere
2003). In eight studies neither the method of randomisation nor
the method of double blinding was described (Brzeski 1991; Deal
1991; Eberl 1988; Leventhal 1993; Leventhal 1994; Tao 1989; Watson
1993; Zurier 1996). One study of topical capsaicin was downgrad-
ed, despite reporting a complete description of the double-blinding
method, because we considered that placebo validity and blinding
may have been compromised by the burning side effect of this top-
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ical intervention (McCarthy 1992). Another study did not address all
incomplete outcome data in the report (Li 2007).
Allocation concealment was assessed according to the Cochrane
format, as described in the methods (Higgins 2008). Allocation con-
cealment was well described and considered adequate in five stud-
ies (Biegert 2004; Chopra 2000; Cibere 2003; Li 2007; Song 2007) but
could not be clearly determined in any other study. Several stud-
ies suffered from other biases such as differences in baselines (eg:
Goldbach-Mansky 2009; Li 2007).
E>ects of interventions
See: Summary of findings for the main comparison; Summary of
findings 2
See: Characteristics of included studies; tables 'Summary of find-
ings; Table 1, 'Details of the herbal medicinal products used for the
treatment of RA'.
Twenty-two studies assessed products from 13 different plant
species. Each herbal intervention was considered separately and
consequently eight studies were discussed independently (Biegert
2004; Chopra 2000; Cibere 2003; Li 2007; Mur 2002; Pattrick 1989;
Sandler 1998; Song 2007) and the remaining studies were grouped
in some manner with studies of the same intervention. Results from
the two crossover studies (Tao 1989; Zurier 1996) were reported on
only up to the point of crossover. Data from a study with a mixed co-
hort (participants with either OA or RA) were separated (Deal 1991)
and the data for participants with RA were reported in this review.
Gamma linolenic acid
Although there were seven studies of gamma linolenic acid (GLA),
the studies were heterogeneous. Three plants oils were used as
sources of GLA (borage seed, blackcurrant seed, evening primrose)
and the approximate percentage of GLA varies among these oils
such that the daily doses of GLA ranged from 525 mg (Watson 1993)
to 2800 mg (Zurier 1996).
Small daily dose GLA (525 mg to 540 mg)
Three studies, each of daily doses of GLA between 525 mg and 540
mg, were incompletely reported and data could not be extract-
ed (Belch 1988; Brzeski 1991; Watson 1993). Results of these three
studies are summarised and reported descriptively. In two of these
studies GLA was administered as evening primrose oil (Belch 1988;
Brzeski 1991) and the third study used blackcurrent seed oil as the
GLA source (Watson 1993).
No significant improvements in visual analogue pain scores were
identified in any of the low dose studies. Morning stiffness, mea-
sured in minutes, was reported in all three studies and found to be
statistically significantly reduced in two studies (Brzeski 1991; Wat-
son 1993). Non-significant trends to improvement in Ritchie index
were reported in two studies (Brzeski 1991; Watson 1993). Trends to
reduced pain, improved grip strength and improved patient global
assessment were also reported in one study (Watson 1993).
Participants' self-assessments generally favoured oils containing
GLA over placebo oils. An improvement in well being was report-
ed by almost all participants receiving blackcurrant seed oil com-
pared with 20% of those receiving the placebo oil (Watson 1993). In
another study 94% of patients receiving evening primrose oil (EPO)
reported a subjective improvement compared to a little over 40%
in the placebo group; after a three-month placebo phase, 80% of
patients taking EPO, compared to 14% of those taking placebo, re-
lapsed at least to their baseline parameters (Belch 1988).
In two of these studies, participants reported whether they reduced
their routine dose of NSAIDs during the intervention period. The in-
tervention periods differed: six months in one study (Brzeski 1991)
and 12 months in the other (Belch 1988), and these data were re-
ported as a dichotomous variable so that the actual amount of
dose reduction was unknown in most cases. In one study, 11 out of
15 people receiving GLA reported reduced or ceased NSAID intake
compared with five participants out of 15 receiving placebo (Belch
1988). In the other study, three participants in each group reported
reduced NSAID intake, by 400 mg ibuprofen daily, and no partici-
pants ceased NSAID use (Brzeski 1991). Also in this study, one par-
ticipant in each of the GLA and placebo groups reported increased
NSAID use (Brzeski 1991). When these data were pooled, the rela-
tive risk of reducing NSAIDs was higher among participants using
GLA than those using placebo oils (RR 1.89, 95% CI 0.96 to 3.76)
(Analysis 1.10). This risk estimate is drawn from studies of small
sample size with incomplete data reporting and is considered low
quality evidence.
Only one study included dichotomous data for participants who re-
ported adverse events: 2 out of 16 participants in the GLA and 0
out of 18 participants in the placebo group (Belch 1988). The rel-
ative risk of adverse events was higher among participants using
GLA than among participants using the placebo oil (RR 5.59, 95% CI
0.29 to 108.38) (Analysis 1.11). The same study reported the number
of participants who withdrew from the study due to worsening dis-
ease: 1 participant out of 16 who received GLA and 10 participants
out of the 18 people who received the placebo oil. These withdraw-
al rates equate to a relative risk of worsening disease in favour of
the placebo group over the GLA group (RR 0.11, 95% CI 0.02 to 0.78)
(Analysis 1.12).
Large daily dose GLA (1400 mg or greater)
Four of studies investigated daily doses of GLA between 1400 mg
and 2800 mg and were adequately reported to allow data extrac-
tion and some data pooling (Jantti 1989; Leventhal 1993; Leventhal
1994; Zurier 1996). Three of these studies reported outcomes for
pain, global evaluation, morning stiffness and joint assessment us-
ing the same outcome measures, and these data were combined
(Leventhal 1993; Leventhal 1994; Zurier 1996). The other study re-
ported outcomes for pain and morning stiffness using different out-
come measures and were reported in isolation (Jantti 1989).
Pain
Pain measured using a 100 mm visual analogue scale (VAS 0 to
100), and reported as percentage change from baseline (Leventhal
1993; Leventhal 1994; Zurier 1996). Using a random-effects model,
pooled results showed significant improvement among people us-
ing GLA compared with people using placebo oils (MD -32.83, 95%
CI -56.25 to -9.42, P = 0.006) (Analysis 1.1). Although these studies
applied slightly different lengths of intervention: 24 weeks (Leven-
thal 1993; Leventhal 1994), six months (Zurier 1996), results dis-
played little heterogeneity (Chi2 1.25, I2 = 0%, P = 0.54) and were
considered as pooled data only. These studies together provided
moderate evidence that approximately six months of daily use of
plant oil in a dose equivalent to at least 1400 mg GLA afforded sta-
tistically significant improvements in self-reported VAS pain scores
in people with RA (Summary of findings table 1).
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In another study (Jantti 1989), 100 mm VAS pain scores were report-
ed as absolute pain scores at the end of the 12-week intervention
period. These results favoured the placebo group with a non-signif-
icant MD of 6.00 (95% CI -16.36 to 28.36, P = 0.60) (Analysis 1.1). It
is unclear why these results differed from those of the other three
large dose studies, but possible explanations include a shorter in-
tervention period (12 weeks), use of a non-inert oil (olive oil) in the
placebo group and a small sample size that may have contributed
to Type II error.
Pain measured using a categorical scale of 0 to 4 (none to very se-
vere) and reported as percentage change from baseline (Leventhal
1993; Leventhal 1994; Zurier 1996) also showed near significant im-
provement among people using GLA compared with people using
placebo oils (MD -34.19, 95% CI -71.57 to 3.18, P = 0.07; data not
shown). These studies were moderately heterogeneous (Chi2 4.95,
I2 = 59.6%, P = 0.08) but within acceptable thresholds for data pool-
ing.
Morning sti>ness
Duration of morning stiffness was measured in minutes. Absolute
values of morning stiffness after 12 weeks of GLA intervention
showed a non-significant improvement in the treatment group (MD
-5.00, 95% CI -41.68 to 31.68, P = 0.79) (Jantti 1989). Measures of
morning stiffness, adjusted to change scores from baseline, were
pooled for the three studies with intervention periods of approxi-
mately six months (Leventhal 1993; Leventhal 1994; Zurier 1996).
These results favoured GLA over placebo (MD -55.07, 95% CI -76.87
to -33.27, P < 0.01) (Analysis 1.2). These three studies together pro-
vided high quality evidence that approximately six months of daily
use of plant oil in a dose equivalent to at least 1400 mg GLA afford-
ed statistically significant improvements in self-reported duration
of morning stiffness in people with RA. Given the previously men-
tioned caveats regarding the three-month study (Jantti 1989), there
was bronze level evidence that shorter duration of treatment with
GLA did not produce significant improvement.
Joint tenderness
Tender joint count out of 68, adjusted as a percentage change
from baseline scores, reduced in favour of GLA in each of the three
longer-term studies (Leventhal 1993; Leventhal 1994; Zurier 1996).
Pooled results of the three studies, using a random-effects model,
returned a MD of -53.80 (95% CI -95.61 to -12.00, P = 0.01) (Analysis
1.3). These studies were substantially hetergeneous (Chi2 6.62, I2
= 69.8%, P = 0.04) but each study returned results in favour of GLA
with none of the 95% CIs extending to favour placebo, indicating
that the findings were consistent but the overall effect (Z = 4.01)
may be considered an estimate within a range.
Using the categorical scale of 0 to 3 (none to severe), improve-
ment in joint tenderness as a percentage change from baseline
was reported among particapnts using GLA in each of the longer-
term studies (Leventhal 1993; Leventhal 1994; Zurier 1996). Pooling
these data and applying a random-effects model returned a MD of
-56.64 (95% CI -98.10 to -15.17, P < 0.01) (Analysis 1.5). Consistent
with the 68 tender joint count scores, these studies displayed sub-
stantial heterogeneity (Chi2 5.69, I2 = 64.9%, P = 0.06) albeit with-
in an acceptable threshold for data pooling. The overall effect (Z =
4.06) should be viewed as a broad estimate of effect size.
When considered together, these three studies provided high qual-
ity evidence that approximately six months daily use of at least 1400
mg GLA afforded statistically significant improvement in joint ten-
derness, measured either as 68 tender joint count or self-reported
categorical grading of tenderness.
Joint swelling
Swollen joint count (out of 66), adjusted as a percentage change
from baseline scores, reduced in favour of GLA in two of the three
studies of approximately six months duration (Leventhal 1993;
Zurier 1996). In the third study (Leventhal 1994) results slightly,
non-significantly favoured placebo (MD 8.00, P = 0.62) but this study
was hampered by small sample size (n = 14) and large variance in
swollen joint count scores (95% CI -124.61 to 140.61). When these
data were pooled, this small sample study had some influence:
MD of -14.43 and the overall effect (Z = 1.66) was not statistical-
ly significant (95% CI -31.43 to 2.56, P = 0.10) (Analysis 1.4). In all
three studies of approximately six-months duration, joint swelling
was also scored on a scale of 0 to 3 (none to severe) and con-
verted to a percentage change from baseline measures. Consistent
with the 66 swollen joint count scores, results in one of the studies
slighty favoured placebo over GLA and shifted the weighted mean
to midline when data were pooled (Leventhal 1994). Applying a ran-
dom-effects model returned a MD of -24.02 (95% CI -70.80 to 22.76)
and a small, non-significant estimate of overall effect (Z = 1.01, P <
0.31) (Analysis 1.6).
Global evaluation
Six out of the seven GLA studies evaluated the global impression of
the intervention. All but one of these (Brzeski 1991) reported that
participants found GLA to be superior to placebo. Due to differences
in scales and the detail of data reporting, data were available for ex-
traction and pooling from three studies only (Leventhal 1993; Lev-
enthal 1994; Zurier 1996). In these studies global evaluations of dis-
ease activity by physician and patient were measured using a 0 to
4 (none to very severe) scale and converted to percentage changes
from baseline scores.
The mean difference for patient global evaluation was -20.87 (95%
CI -39.43 to -2.31, P = 0.03) (Analysis 1.8). These three studies to-
gether provided high quality evidence that daily treatment with at
least 1400 mg of GLA over approximately six months afforded sta-
tistically significant improvement in self-reported evaluation of dis-
ease severity over placebo intervention among people with RA.
Pooled data for physician global evaluation returned a non-signif-
icant MD of -21.28 (95% CI -70.52 to 27.95, P = 0.40) (Analysis 1.9).
Global evaluation by physicians showed substantial and unaccept-
able heterogeneity between the studies (Chi2 11.20, I2 = 82.1%, P
< 0.01). In only one of these three studies was the procedure for
the physician fully described and made it clear that all assessments
of disease activity in any individual were undertaken by the same
physician throughout the trial (Zurier 1996). The other two studies
may have been compromised by inter-rater variability (Leventhal
1993; Leventhal 1994).
Adverse events
Dichotomous data for participants who reported adverse events
was reported in one low dose (Belch 1988) and one higher dose
study (Leventhal 1993). The risk of adverse events tended to be
higher among participants using GLA (any dose) than among par-
ticipants using the placebo oil, but this did not reach statistical sig-
nificance (RR 4.24, 95% CI 0.78 to 22.99; Analysis 1.11).
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Tripterygium wilfordii Hook F - oral
Although undertaken by the same research team, data from three
studies of oral administration of Tripterygium wilfordii Hook F
(TwHF) could not be pooled because the interventions and mea-
sures differed between the trials (Goldbach-Mansky 2009; Tao 1989;
Tao 2002).
A 60 mg daily dose of TwHF was compared with placebo in a
crossover trial, the first arm of which lasted for 12 weeks. Clini-
cal outcome measures were: joint tenderness (0 to 3, none to se-
vere), joint swelling of 60 joints only, morning stiffness (in hours),
grip strength (mm Hg), and 15-metre walking time (in seconds). Im-
provements in each of these measures were reported in favour of
TwHF (Tao 1989). Statistically significant decreases were found in
joint tenderness (MD -14.00, 95% CI -19.02 to -8.98, P < 0.01) (Analy-
sis 2.1) and 60 swollen joint count (MD -3.10, 95% CI -5.53 to -0.67,
P = 0.01) (Analysis 2.2). Non-significant decreases were reported in
morning stiffness (MD -1.40, 95% CI -4.18 to 1.38, P = 0.32) (Analysis
2.3) and 15-metre walking time (MD -10.40, 95% CI -22.07 to 1.27, P
= 0.08) (Analysis 2.5). An increase in grip strength was also demon-
strated (MD 3.20, 95% CI -20.01 to 26.41) (Analysis 2.4) but this im-
provement was not large enough to be statistically significant (Z =
0.27, P = 0.79).
In the second study, larger doses of TwHF were used and compared
to placebo in high (360 mg) and low (180 mg) daily doses. Clinical
outcomes were assessed using the American College of Rheumatol-
ogy (ACR) core set of measures at the 20%, 50% and 70% improve-
ment levels (Tao 2002). Eight out of 10 participants in the high dose
group and 4 out of 10 participants in the low dose TwHF group sat-
isfied the ACR20 improvement criteria at the end of the intervention
period. No participants in the placebo group satisfied these crite-
ria. These dichotomous data converted to a risk ratio of 10.64 (95%
CI 0.64 to 176.54) (Analysis 3.1) for satisfying ACR20 improvement
criteria when taking 180 mg TwHF compared with placebo and a
risk ratio (RR) of 20.09 (95% CI 1.30 to 310.16) (Analysis 4.1) for the
same improvement when taking 360 mg TwHF rather than place-
bo. Graphic presentation of between group comparisons of each
of the disease activity component measures (tender joint count,
swollen joint count, pain, physical function, patient global, physi-
cian global, erythrocyte sedimentation rate, C-reactive protein) in-
dicated that all outcomes were improved in the high dose group
over both the low dose and placebo groups and, similarly, that im-
provements were observed on all measures in the low dose group
over the placebo group. These data were not reported in a form that
allowed extraction for re-analysis.
In the most recent study, 180 mg of TwHF (given as 60 mg three
times per day) was compared with 2000 mg sulphasalazine (1000
mg twice per day) over 24 weeks with clinical (ACR20, ACR50,
ACR70, and DAS28) and laboratory (ESR, serum C reactive protein,
interleukin-6) outcome measures collected at baseline, week 2,
week 4, and every 4 weeks thereafter (Goldbach-Mansky 2009). This
study was hampered by large withdrawals from both treatment
groups (TwHF: commenced n =60, withdrew n=23, completed n=37;
sulfalazine: commenced n=61, withdrew n=36, completed n=25).
Using an intention-to-treat analysis with mixed effects modeling,
to account for all randomised participants, 65.0% of participants
receiving TwHF (95% CI 51.6% to 76.9%) and 32.8% of participants
receiving sulfalazine (95% CI 21.3% to 46.0%) were predicted to
be ACR20 responders (P = 0.001). Re-analysis of response to treat-
ment using ACR20 as a dichotomous variable supports this finding
of a better response in the TwHF group compared with placebo (RR
1.98, 95% CI 1.32 to 2.97; Analysis 5.1). In both groups the ACR20
response occured as early as two weeks after commencing treat-
ment, but at all time points the percentage of participants predict-
ed (modelled) as ACR20 responders was significantly greater in the
TwHF group. The TwHF group also demonstrated a higher percent-
age of ACR50 (P < 0.001) and ACR70 (P < 0.002) responders at all time
points, and lower interleukin-6 levels and less radiographic pro-
gression (non-significant). Re-analysis response to treatment using
ACR50 as a dichotomous variable supports this claim of a better
response in the TwHF group compared with sulfalazine (RR 20.33,
95% CI 2.82 to 146.75; Analysis 5.2).
Adverse events
In the first two studies, more adverse reactions were seen among
people receiving TwHF than people receiving placebo (Analysis 3.3;
Analysis 4.3). In the first study, adverse reactions resulted in four
withdrawals and a severe reaction (fever and aplastic anaemia) oc-
curred in one participant following an overdose of TwHF (Tao 1989).
One death occurred also, although not thought to be related to
the intervention (Tao 1989). In the second study, four participants
in the placebo group reported adverse reactions as did six partici-
pants in the high dose group and five participants in the low dose
group (Tao 2002). In this study none of the adverse reactions were
reported as severe, that is participants did not require hospitali-
sation. Commonly reported adverse reactions included diarrhea,
headache and hair loss.
In the third study 53 participants in the TwHF group and 55 in the
sulfalazine group reported adverse events, and the proportions
were not significantly different (RR 0.98, 95% CI 0.87 to 1.11; Analy-
sis 5.4), however a notably greater proportion of participants spec-
ified that they withdrew due to adverse events from the sulfalazine
group than from the TwHF group such that the relative risk of with-
drawal due to adverse events markedly favours the TwHF group
(Analysis 5.5). Most adverse events affected the gastrointestinal
tract (59% TwHF, 49% sulfalazine), and were more often moderate
to severe in the sulfalazine group than in the TwHF group (P = 0.039)
(Goldbach-Mansky 2009).
Phytodolor® N
Two studies compared a daily dose of 30 drops of Phytodolor® N
(prepared from ash bark, aspen leaf, aspen bark, golden rod herb)
to placebo, one over two weeks (Meier 1987) and the other over 12
months (Eberl 1988). Both studies were unpublished randomised
controlled clinical trials conducted by the manufacturer (Steiger-
wald Pharmaceuticals) as part of product development and testing.
Because length of intervention and some of the measures differed
between the trials, data could not be pooled for meta-analysis. For
one study, mean changes from baseline were calculated from fre-
quency tables reported in the paper (Eberl 1988). Standard devia-
tions could not be calculated for some outcomes (eg, NSAID use),
and thus such data could not be extracted for analysis in this re-
view.
Data from single trials indicate no differences between participants
treated with Phytodolor® N and placebo in terms of pain at two
weeks (Analysis 6.1), joint swelling after two weeks of treatment
(Analysis 6.2), or morning stiffness at 12 months follow-up (Analysis
6.3). There was more improvement in disease following treatment
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with Phytodolor® N, as measured by the Ritchie index at 12 months
(Analysis 6.4).
Both studies reported cumulative use of NSAIDs (diclofenac) over
the course of the trial. Data could be extracted from one trial
(Eberl 1988). There was no difference in the NSAID use in partic-
ipants treated with Phytodolor® N group compared with partici-
pants treated with placebo at one month or 12 months. (Analysis
6.5).
For several herbal medicines, only one study was available.
SKI306X
In a single, well designed, multi-centre trial, the Korean herbal mix-
ture SKI 306X was tested against celecoxib in a six-week head-to-
head comparison (Song 2007). The authors reported prior studies
as evidence of anti-inflammatory and analgesic effects, but these
were in vitro or animal studies and were not suitable for inclusion
in this review.
Pain, measured using a 100 mm visual analogue scale, decreased
significantly in both groups over time (P < 0.01), as reported by the
trial authors, but was not significantly different between groups
(Analysis 7.1). These results provided moderate quality evidence
that SKI306X was comparable to celecoxib for pain reduction in
people with RA.
After three weeks of intervention, 16 participants in the SKI306X
group and 24 participants in the celecoxib group satisfied the
ACR20 improvement criteria. After six weeks of intervention, equal
numbers of participants (n = 29) in both groups satisfied these crite-
ria (Analysis 7.2). Considering each of these criteria individually: 28
tender joint count; 28 swollen joint count; patient's global assess-
ment; investigator's gloal assessment; Health Assessment Ques-
tionaire Disability Index (HAQ-DI) score; Westergren erythrocyte
sedimentation rate (ESR), c-reactive protein (CRP); there were no
significant differences between the two groups at baseline, week
three or week six on any measure except ESR (data not shown). The
triallists reported that mean ESR was slightly but not significantly
higher in the SKI306X group at baseline and dropped to significant-
ly less than the mean ESR in the celecoxib group at both three-week
(P < 0.04) and six-week (P = 0.01) measurements. These results of-
fered moderate quality evidence that SKI306X and celecoxib had
comparable effects on reducing disease activity in people with RA.
Adverse events did not differ significantly between the two groups
(Analysis 7.3). Gastrointestinal complaints (epigastric pain, abdom-
inal discomfort, nausea, anorexia, dyspepsia) were most common.
In the SKI306X group, one participant who reported depression
and one participant who reported epigastric pain discontinued the
study medication. In the celecoxib group, three participants who
reported pruritus, abdominal discomfort and skin rash, respec-
tively, discontinued the study medication. The person who experi-
enced depression in the SKI306X group was hospitalized and this
incident was reported as a serious drug-related event.
Willow bark
A proprietary extract of willow bark (Salix daphnoides) equivalent
to 240 mg salicin was compared with placebo in a small sample
(n = 26) of people with RA. Over six weeks of intervention willow
bark was not significantly more effective than placebo in produc-
ing a change from baseline in any clinical outcome: pain VAS 0 to
100 (Analysis 8.1); 28 tender joint count (Analysis 8.2); 28 swollen
joint count (Analysis 8.3); patient assessment of efficacy (Analysis
8.4); physician assessment of efficacy (Analysis 8.5); HAQ-DI score
(Analysis 8.7); SF-36 physical component summary score (Analysis
8.8); SF-36 mental component summary score (Analysis 8.9). This
lack of statistical significance may be a Type II error in a small sam-
ple, underpowered study.
Two participants in the willow bark group and one participant in the
placebo group satisfied ACR20 response criteria after six weeks of
intervention; this difference was not statistically significant (Analy-
sis 8.6). Similar numbers and severities of adverse events were re-
ported for both the willow bark and placebo groups; seven adverse
events were reported in each group, although it was unclear how
many participants these reports represented.
Cat's claw
Uncaria tomentosa (cat's claw) was compared with placebo in a
double-blind randomised controlled trial. The trialists report sig-
nificant improvements in the 68 tender joint count both within and
between groups after 24 weeks of daily use (P = 0.044) (Analysis 8.2).
Also, significant within group improvements were found in the in-
tervention group on measures of 66 tender joint count (P = 0.001)
(Analysis 8.3), Ritchie index (P = 0.002) (Analysis 8.5) and duration
of morning stiffness (P = 0.002) (Analysis 8.4). We could not veri-
fy the results independently as no appropriate measures of vari-
ance were available for the trial for extraction. The trialists report
no improvements, either between or within groups, were reported
for any other clinical or laboratory variables. Twelve participants
in each group reported side effects and one participant from each
group withdrew from the study because of these effects.
Feverfew
Daily use of dried, powdered feverfew (Tanacetum parthenium) was
compared with placebo (cabbage) in 41 people with RA. Of the clin-
ical outcomes (duration of morning stiffness, inactivity stiffness,
pain 10 cm VAS, grip strength, Ritchie index) measured in this study
(Pattrick 1989) data were presented for grip strength only. Grip
strength was reported to be significantly improved in the feverfew
group over time (P = 0.03) and in comparison to the placebo group
after six weeks of intervention (P = 0.047) but re-calculation of the
between group comparison for this review returned a non-signifi-
cant difference between groups (MD 17.00mmHg; 95% CI -8.65 to
42.65mmHg) (Analysis 9.1). No significant differences were report-
ed either between or within groups on any other clinical measures.
One participant in each group reported mild side effects and the
participant from the placebo group withdrew from the study be-
cause of these effects (Analysis 9.2).
RA-1
An Ayurvedic herbal mixture, RA-1, was compared with placebo in
people with RA. Data from 182 participants were available for inclu-
sion in an intention-to-treat analysis although only 165 participants
completed the full 16-week trial. No statistically significant differ-
ences were identified between the groups on any clinical measures
after 16 weeks of intervention, however change scores on all clinical
variables were greater in the RA-1 group than in the placebo group.
Among participants who completed the entire 16-week trial, clini-
cal outcomes were further assessed using the ACR core set of mea-
sures at the 20% and 50% improvement levels (Chopra 2000). Thir-
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ty-nine out of 80 participants in the RA-1 group and 30 out of 85
participants in the placebo group satisfied the ACR20 improvement
criteria at the end of the intervention period; this difference did not
reach statistical significance (risk ratio 1.38; 95% CI 0.96 to 1.99)
(Analysis 10.7). However, a significantly greater number of partici-
pants receiving RA-1 improved, as measured by the ACR50 improve-
ment criteria: 15 out of 80 participants in the RA-1 group and 5 out
of 85 participants in the placebo group (risk ratio 3.19; 95% CI 1.21
to 8.37) (Analysis 10.8).
Boswellia serrata
An extract of Boswellia serrata (H15) was tested in 78 participants
with active RA in two randomised controlled trials in four cen-
tres. Results from 37 participants in one centre (Ratingen) were
re-analysed and demonstrated no significant benefit over placebo
in either clinical or laboratory outcomes (Sandler 1998). The da-
ta were not normally distributed and were consequently reported
as median and range. Data in this form could not be extracted for
analysis in this review. Median subjective pain assessments (VAS 0
to 10) worsened from 4.6 to 4.7 in the intervention group and im-
proved from 3.9 to 3.8 in the placebo group, however the placebo
group were somewhat favoured by lower baseline pain scores. Me-
dian subjective global assessment improved in both groups, from
5.0 to 4.9 in the intervention group and from 4.7 to 4.2 in the placebo
group. Participant-reported adverse events did not differ between
groups; three of 19 participants in the placebo group, and one of 18
in the treatment group had adverse events (Analysis 11.1).
Capsaicin - topical
Topical capsaicin for control of rheumatoid arthritic hand pain was
compared to placebo in two studies of people with RA. In both
studies the placebo was a vehicle cream prepared and packaged
to appear indistinguishable from the active agent, but blinding and
placebo validity may have been compromised by a local burning
sensation that may occur as a side effect with topical capsaicin. In
one study, burning at the site of application was noted by 44% of
participants treated with capsaicin and by one treated with place-
bo (Deal 1991).
In the larger of the two trials (n = 31), four times daily topical use
of 0.025% w/v capsaicin cream was compared to placebo (Deal
1991). Improvements in pain were measured on a 100 mm visu-
al analogue pain scale and a categorical pain scale. On both mea-
sures participants in the capsaicin group reported greater improve-
ment than participants in the placebo group. Percentage change
in pain from baseline on the 100 mm VAS showed a MD of -25.00
mm (95% CI -51.76 to 1.76) (Analysis 12.1) and using the categorical
pain scale showed a MD of -0.47 (95% 95% CI -1.08 to 0.14) (data not
shown). Although these between group differences were not sta-
tistically significant, they demonstrated a trend to improvement.
Small sample size meant that this study was probably underpow-
ered, increasing the likelihood of Type II error. A change from base-
line of the physician's global evaluation (-1 to 3, higher score in-
dicating greater improvement) also favoured the treatment group
and the difference between groups in this measure was statistically
significant after four weeks of intervention (MD 1.36, 95% CI 0.52 to
2.20, P = 0.001) (Analysis 12.2). Burning at the site of application of
the cream was the only adverse reaction reported in this study.
A further study compared a higher dose (0.075% w/v) of capsaicin
cream to placebo (McCarthy 1992). The sample size of this study
was very small; seven participants were recruited and five complet-
ed the four week trial. Although improvements in pain were mea-
sured using a 100 mm visual analogue pain scale, data from this
study were not adequately reported to allow extraction for pooled
analysis with the larger study.
Tripterygium wilfordii - topical
Sixty-one people with RA participated in a six-week, randomised,
double-blind, placebo-controlled trial of a tincture of Tripterygium
wilfordii. The placebo tincture was prepared and packaged to be
indistinguishable from the intervention. The herbal medicine was
applied topically to the swollen or tender joints up to six times per
day and results were reported using the core set of ACR response
criteria, aggregated into a slightly modified form of the 20% im-
provement level (ACR20). At the end of the intervention period, sta-
tistically significant differences, in favour of Tripterygium wilfordii,
were identified on most clinical outcomes: 42 tender joint count
(MD 1.50, 95% CI 0.58 to 2.42, P = 0.001) (Analysis 13.1), 40 swollen
joint count (MD 4.40, 95% CI 2.76 to 6.04, P < 0.001) (Analysis 13.2),
grip strength in kiloPascals (MD 39, 95% CI 25.70 to 52.30, P < 0.001)
(Analysis 13.3) and duration of morning stiffness measured in hours
(MD 0.80, 95% CI 0.54 to 1.06, P < 0.001) (Analysis 13.4).
Treatment with Tripterygium wilfordii resulted in improved disease
activity, as measured by the number of ACR20 responders: 18 out
of 31 participants in the intervention group compared with 6 out of
30 participants in the placebo group (risk ratio 2.90, 95% CI 1.34 to
6.31, P = 0.007) (Analysis 13.5).
Ganoderma lucidum and San Miao San
Sixty-five participants were randomised to two groups: 32 partici-
pants received a Traditional Chinese Medicine preparation combin-
ing 4000 mg Ganoderma lucidum and San Miao San (SMS; compris-
ing 2400 mg Rhizoma atractylodis, 2400 mg Cotex phellodendri, and
2400 mg Radix achyranthes Bidentatae) while 33 participants re-
ceived a placebo (identical looking capsules containing starch and
colouring agent) for 24 weeks (Li 2007). Outcome measures (ten-
der joint count, swollen joint count, patient global assessment on
0-100mm VAS, physician global assessment on 0-100mm VAS, du-
ration of morning stiffness, plasma C reactive protein level, ESR)
were taken at baseline, and ever 4 weeks for 24 weeks. Primary out-
come measure was the count of participants who achieved ACR20
criteria, and secondary outcomes were changes in the individual
components of the ACR20 core set of measures. Some other lab-
oratory investigations were included, but are of no importance in
this review. Despite repeated measures, all analyses were reported
as univariate tests (paired t-tests and Wilcoxon's signed rank test).
Repeated outcomes were reported as percentage change and in-
terquartile range at each time point. After 24 weeks of intervention
15% of the Ganoderma lucidum and SMS group and 9.1% of the
placebo group achieved ACR20; this difference was not statistically
different (RR 0.54, 95% CI 0.11 to 2.70; Analysis 14.1).
Treatment with Ganoderma lucidum and SMS resulted in signifi-
cant improvement in self-reported pain from week 4, maintained
to week 24 (mean ± SD score: 4.9 ± 2.3 at baseline, 4.1 ± 2.3 at week
four, 3.9 ± 2.5 at week 24; P < 0.05). In addition, the patient glob-
al assessment also improved significantly at week 4 and was main-
tained to week 24 (mean ± SD score: 5.7 ± 2.5 at baseline, 5.3 ± 2.5
at week 4, 4.7 ± 2.6 at week 24; P < 0.05). Other ACR components re-
mained unchanged in both groups. There were no differences be-
tween groups at the end of treatment in the percentage, absolute
counts and ratios between CD4, CD8, natural killer and B lympho-
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cytes. Also, CD3, CD4 and CD8 lymphocyte counts and markers of
inflammation, including plasma interleukin-18 (IL-18), interferon
(IFN)–inducible protein 10, monocyte chemoattractant protein 1,
monokine induced by IFN and RANTES (egulated on Activation Nor-
mal T Cell Expressed and Secreted), were unchanged.
Thirteen patients reported 22 episodes (14 in the placebo group
and eight in the Ganoderma lucidum and SMS group; Analysis 14.2)
of mild adverse effects including gastrointestinal upset, palpita-
tions and irregular period (most of these occuring in the placebo
group). There were two episodes of sweating in the Ganoderma lu-
cidum and SMS group with no such symptom reported in the place-
bo group (Li 2007).
D I S C U S S I O N
See: Additional tables, 'Summary of findings'
Definition of herbal medicine and herbal medicinal
products (HMPs) studied
According to the WHO guideline (WHO 1996), herbal medicines are
defined as being finished, labelled medicinal products that con-
tain aerial or underground parts of plants or other plant materi-
al, or combinations thereof, whether in the crude state or as plant
preparations, as active ingredients. Plant materials combined with
chemically defined active substances, including chemically de-
fined, isolated constituents of plants, are not considered to be
herbal medicines. Plant preparations include comminuted or pow-
dered plant materials, extracts, tinctures, fatty or essential oils, ex-
pressed juices and preparations whose production involves frac-
tionation, purification or concentration.
The HMPs studied included preparations from the root of
Tripterygium wilfordii, Clematis mandshurica, Trichosanthes kir-
ilowii, Atractylodes macrocephala, Achyranthes bidentatae; from
the bark of Salix daphnoides, Uncaria tormentosa, Populus trem-
ula, Fraxinus excelsior, Phellodendron chinense; from the herb of
Solidago virgaurea; from the  leaf of Populus tremula, Tanacetum
parthenium; from the flower of Prunella vulgaris, from the seed of
Capsicum frutescens, Oenothera biennis, Ribes nigrum, Borago of-
ficinalis; and from the gum resine of Boswellia species were used
alone or as mixtures. Another HMP included the Ayurvedic mixture
RA1.
The active principle of a herbal medicinal product which is the
sum of all the constituents that produce a medicinal action has
not yet been fully identified for any of the anti-inflammatory herbal
medicinal products. Constituents that contribute to the anti-in-
flammatory or analgesic effects include triptolide and its deriv-
atives (Tripterygium wilfordii), boswellic acids (Boswellia serra-
ta), alkaloids (Uncaria tormentosa), flavonoids (Salix daphnoides),
parthenolide (Tanacetum parthenium), gammalinolenic acid (seed
oils of Oenothera biennis, Ribes nigrum, Borago officinalis), oth-
er unsaturated fatty acids (SKI306X®) and capsaicin (Capsicum
frutescens). Salicin, the characteristic constituent of Salix species,
is an ineffective prodrug; however, during absorption salicin is me-
tabolized into co-active salicylic acid derivatives. Surprisingly, the
amount of salicylic acid produced from a daily dose of Salix bark
extract containing 240 mg of salicin corresponds to an aspirin dose
of only 100 mg, a cardioprotective rather than an anti-inflammato-
ry dose (Schmid 2001). However, this Salix extract dose cannot be
used to replace aspirin as a blood thinner since it was shown not to
have a major impact on blood clotting (Krivoy 2001).
Summary of main results
In general, we found minor evidence that three herbal medicines
may have some effectiveness in the treatment of rheumatoid
arthritis (RA). Oral Tripterygium wilfordii products (TwHF) may im-
prove some symptoms of RA. Across all three trials the results
favoured TwHF and in particular it appears that a dose between 180
mg and 360 mg of TwHF is superior to placebo and superior to, or at
least as effective as, sulfasalzine, for some measures. The beneficial
effect of TwHF may appear as soon as two weeks after commenc-
ing therapy. However, the oral use of Triperygium wilfordii may be
associated with several side effects, some potentially severe, and
therefore this product should be used with caution. Some of the ad-
verse events described in the literature for this herbal medicine in-
clude dysmenorrhoea, decreased male fertility, renal insufficiency,
hematotoxicity, embryotoxicity and immune suppression demon-
strated by increased rate of infections (Canter 2006); the subacute
toxicity showed pathological changes mainly in the lymphatic and
reproductive systems. Therefore, Tripterygium wilfordii Hook F has
a high risk-benefit ratio (Canter 2006). Future research could at-
tempt to replicate the findings of these trials and perform a more
comprehensive evaluation of the safety of this intervention.
There is moderate evidence of benefit for oils containing GLA (that
is borage, blackcurrant, evening primrose oil (EPO)) but an ade-
quate dose and the duration of treatment are unknown (Summa-
ry of findings for the main comparison). Some studies suggest that
effects were not expected to occur for at least six to 12 weeks af-
ter commencing daily use of GLA (Leventhal 1993), with actual ef-
fects being seen at six months (Brzeski 1991) although some man-
ufacturers of GLA suggest a 12-month period of treatment. In gen-
eral, the studies included in this review administered lower doses
of GLA over relatively short periods of time (between 525 mg and
540 mg for six to 12 weeks) or large doses over longer periods of
time (1.4 g to 2.8 g over 24 weeks). The benefits appeared to be
greater if dosages were at least 1.4 g per day and were administered
for at least six-months duration (Summary of findings table 1). The
authors do point out that a problem was encountered where larg-
er doses of GLA were given since this resulted in a large number
and large size of capsules having to be taken. We suggest that fu-
ture studies evaluate the effects of lower dosages over longer pe-
riods of time. There is some concern over the safety of one source
of GLA, EPO. For EPO, allergy or hypersensitivity has been report-
ed but appears to be rare. Also, there have been several reports of
seizures in individuals taking EPO, particularly in people with a his-
tory of seizure disorders or among individuals taking EPO in combi-
nation with anaesthetics or other centrally acting drugs (for exam-
ple chlorpromazine, thioridazine, trifluoperazine or fluphenazine).
Other possible adverse events include occasional headache, ab-
dominal pain, nausea and loose stools. Although some animal stud-
ies showed that GLA decreased blood pressure, human studies do
not show consistent changes in blood pressure. Even so, it is ad-
vised that people on blood pressure medications should closely
monitor their blood pressure when taking EPO. Finally, there are
suggestions in the literature that individuals should stop taking
EPO two weeks prior to surgery that requires general anaesthesia.
Since borage and blackcurrant seed oils also contain GLA, the ad-
verse event profile of EPO might apply to these oils as well (NLM
2009).
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There appears to be some evidence of efficacy for Phytodolor® N
at a dose of 30 drops per day compared to placebo, as reported
in two unpublished studies (Eberl 1988; Meier 1987). These studies
were conducted by the product manufacturer. They were poorly re-
ported and had different durations (two weeks versus 12 months),
therefore they should be replicated by an independent group be-
fore we can definitively establish efficacy. Although the adverse
effect profile for Phytodolor® N appears to be better than for the
NSAIDs included in the trials, gastrointestinal complaints were re-
ported (2.6%) and occasional allergic skin reactions. It has been
proposed that some of the adverse effects are partly due to the al-
cohol content of Phytodolor® N (45.6% volume, 0.7 g per 40 drops)
which may pose a health risk to children and to adults with liver
disease, alcoholism, epilepsy or brain-damage. Caution is advised
during pregnancy or lactation and for drivers and individuals who
operate machinery although no impairment of consciousness or re-
activity is expected to occur with 0.7 g of alcohol per dose. Animal
studies on mutagenicity, teratogenicity and toxicity have indicated
no evidence for toxic effects arising from the intake of the combina-
tion during pregnancy or the lactation period (Gundermann 2001).
All other herbal medicines that were included were tested in single
trials only, most of which were at a high risk of bias and were poor-
ly reported. Therefore no other herbal interventions have evidence
for efficacy. See the characteristics of included studies for details of
all the included trials.
Overall, it was difficult to make definitive conclusions in this review
because of the poor reporting of important information in the in-
cluded trials. To allow full and accurate assessment of future stud-
ies, we recommend that authors conform to the Consolidated Stan-
dards of Reporting Trials (CONSORT) (Moher 2001) and in particular
the recent extension of the CONSORT statement for trials of herbal
interventions (Gagnier 2006a; Gagnier 2006b).
The WHO guideline recommends that the manufacturing proce-
dure should be described in detail (WHO 1996). If other substances
are added during manufacture, in order to adjust the plant prepa-
ration to a certain level of active or characteristic constituents or
for any other purpose, the added substances should be mentioned
in the manufacturing procedures. A method for identification and,
where possible, assay of the plant preparation should be added.
If identification of an active principle is not possible, it should be
sufficient to identify a characteristic substance or mixture of sub-
stances (for example 'chromatographic fingerprint') to ensure con-
sistent quality of the preparation.
The minimum information given for a HMP in a publication should
include the plant part, the brand name if the preparation has not
been solely prepared for the study, the excipient added and the
drug extract ratio if extracts were used, the daily dosage of powder
or native extract (otherwise the extract dose may also contain addi-
tives) and the content of at least one characteristic substance in the
daily dosage. Not all of the articles reporting the results of clinical
trials with HMPs for the treatment of RA provided this information.
The results of such studies are only attributable to the particular
HMP used and cannot be transferred to other HMPs from the plant
material unless these have shown to be bioequivalent (having the
same active principle). HMPs with insufficient declaration includ-
ed those from Tripterygium wildordii (topical preparation and T2),
Uncaria tomentosa, Boswellia serrata, the Ayurvedic mixture RA1,
a herbal mixture from Atractylodes macrocephala,  Phellodendron
chinense and Achyranthes bidentatae that also contained a mush-
room extract. The studies providing sufficient declaration to repeat
the clinical trial were those investigating HMPs from Tripterygium
wildordii (study medication), Salix daphnoides, Tanacetum parthe-
nium, the herbal mixtures SKI306X®  and Phytodolor®, the active
principle of Capsicum frutescens and the seed oils of Oenothera bi-
ennis, Ribes nigrum and Borago officinalis, all standardized with
gammalinolenic acid. For the details see the 'Additional table'.
Further investigation of each herbal therapy is warranted, partic-
ularly via well designed, fully powered confirmatory clinical trials
that use American College of Rheumatology criteria to measure
outcomes (ACR 2002).
Overall completeness and applicability of evidence
As described above, although we included 22 randomised con-
trolled clinical trials only three of the herbal medicinal products
were tested in two or more trials. Therefore, there is inadequate
evidence for most of the included herbal medicinal products. Also,
for those herbal medicines that were tested in two or more trials,
the trials frequently differed in important ways such that no single
finding was supported by additional trials. Therefore, it is very diffi-
cult to make definitive conclusions except to say that this evidence
as a whole is not complete and does not provide import to clinical
practice. That is, the external generalizability of the data described
in this review is poor. More research is needed to confirm any of
the findings reported in this review. In addition, we suggest that
more comparative trials are needed to determine how these inter-
ventions compare to other (standard) interventions for rheumatoid
arthritis.
Quality of the evidence
Of the 22 studies included in this review only three were at a low
risk of bias. All other studies were considered to be at a high risk of
bias. Also, trials frequently under-reported important information
necessary for the assessment of risk of bias. As described above,
we suggest that authors refer to the Consolidated Standards of Re-
porting Trials (CONSORT) (Begg 1996; Moher 2001) and in particular
the recent extension of the CONSORT statement for trials of herbal
interventions (Gagnier 2006a; Gagnier 2006b). These widely pub-
lished and accepted guidelines clearly describe the necessary in-
formation to be included in a report of a controlled trial of a herbal
medicine intervention.
Furthermore, trials testing the same herbal species or product fre-
quently differed in the participant, intervention and outcome mea-
sure characteristics. Due to the extensive heterogeneity, further
clinical trials that are similar to those initially positive trials report-
ed above are needed for convincing evidence of effectiveness. Al-
so, many of the studies were inconsistent with current clinical tri-
al standards in rheumatology. For example, only seven of the 22
studies used the set of outcome measure recommended by the
American College of Rheumatology (ACR) since 1995 (Biegert 2004;
Chopra 2000; Cibere 2003; Goldbach-Mansky 2009; Li 2007; Song
2007; Tao 2002). For future studies, we recommend that trialists
use ACR outcome measures to allow comparison of effect sizes be-
tween different herbal medicines and to provide estimates of clin-
ical relevance. In addition, very few trials compared herbal medi-
cines against standard therapies. We recommend that future trials
have comparative designs and include measures of the costs of care
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so that the direct costs of these interventions might be compared
with the costs of other RA treatments.
Although some of the trials included adverse event data, adequate
evidence of safety is not available for any of the herbal medici-
nal products considered in this review. We recommend that fu-
ture studies be done on genotoxicity, toxicokinetics and mecha-
nisms as these are essential for preclinical safety assessment (ICH
2004). We also recommend pharmacological trials of six and nine-
month chronic toxicity assessment in rodents and non-rodents, re-
spectively. The herbal medicinal products considered in this re-
view have not been subject to this rigorous non-clinical testing and,
therefore, cannot be recommended during pregnancy or lactation.
In addition, it is important to test for contaminants as herbal prepa-
rations may be contaminated with other herbs, pesticides, herbi-
cides, heavy metals or drugs. However, contamination is unlikely
if the manufacturer complies with the principles and guidelines of
good manufacturing practice (GMP) (EFPIA 1996).
Potential biases in the review process
This review has several strengths. First, we conducted a compre-
hensive electronic search strategy. Next, we decided on inclusion
of trials, extracted the data and performed risk of bias assessments
in duplicate at a minimum. Also, we searched for and included tri-
als in all languages and in any year. This review may have several
drawbacks. First of all, the indexing of herbal medicine trials is not
consistent across databases, therefore we might have missed trials.
This is unlikely given our carefully developed search strategy. Final-
ly, we did not conduct any meta-analyses due to the heterogeneity
of the included trials but instead described the trials in a qualitative
manner. In agreement with others, we feel that this form of qualita-
tive description of trials is warranted in the face of a high degree of
heterogeneity across trials included in a systematic review (Furlan
2009; Higgins 2008).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The current available evidence for herbal treatment of RA is gener-
ally sparse and reliant on small sample sizes and is therefore insuf-
ficient for any reliable assessment of efficacy to be made. The vari-
ability between studies indicates a need to establish efficacy, op-
timum dosage and duration of treatment for these interventions.
The single studies are inconclusive.
Good tolerance of most of the herbal remedies was demonstrated
although caution is warranted in interpreting safety due to small
sample sizes of some studies and the incomplete examination of
safety profiles of these interventions.
Implications for research
Although this review has not been able to provide conclusive evi-
dence for the use of herbal therapy in RA, some of the studies are
of sufficiently high quality to encourage further research, especial-
ly to confirm the efficacy and optimum dosage of GLA.
The trend for self-medication with over-the-counter herbal reme-
dies, especially in the treatment of chronic disease, makes further
research in the field desirable. Non-clinical studies are required to
determine the toxicity profiles of almost all herbal medicines in
common use for the treatment of RA.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomised, double blind, placebo control, 3 parallel groups. Duration 12 months.
Participants Randomised n=49, completed n=34. Age range 28-74 yr. Inclusion: classical or definite RA (ARA criteria),
requiring NSAIDs but not DMARDs.
Interventions Tradename not provided, Oenothera biennis (evening primrose), oil, 6000mg (12x500mg, approx 9%
GLA, equivalent to 540mg GLA), capsules, oral. Concurrent intervention: usual NSAIDs for first 3 months
only.
Outcomes Morning stiffness (minutes), grip strength mmHg, Ritchie index, pain VAS 0-100, patient global.
Notes Results favour intervention for reduction in pain and NSAID use. No evidence of disease-modifying ef-
fects.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat analyses.
Free of selective report-
ing?
Low risk Reported adverse events.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria.
Belch 1988 
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 6 weeks.
Participants Randomised n=26 (intervention n=13, control n=13), completed n=26 (intervention n=13, control n=13).
Age (yr): intervention m=56.5 sd=8.9, control m=60.1 sd=11. Inclusion: ACR criteria RA stage I-III.
Interventions Assalix*, Salix daphnoides cortex (willow bark), ethanolic extract, 1572.96mg (2x2x393.24mg, equiva-
lent to 240mg salicin), tablets, oral.
Outcomes Pain VAS 0-100, tender joint count, HAQ-DI, stiffness VAS 0-100, efficacy VAS 0-100, SF-36, ESR, CRP,
ACR20.
Notes Results equivocal.
Biegert 2004 
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Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Randomised to one of three groups using a computer generated random num-
ber sequence.
Allocation concealment? Low risk Adequate.
Blinding? 
All outcomes
Low risk Active interventions and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat and per protocol analyses.
Free of selective report-
ing?
Low risk Confirmatory study, statistical power reported.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria.
Biegert 2004  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 6 months.
Participants Randomised n=40 (intervention n=19, control n=21), completed n=30 (intervention n=13, control n=17).
Age range 16-75 yr. Inclusion: classical or definite RA, all with probable gastro-intestinal lesions due to
NSAIDs.
Interventions Tradename not provided, Oenothera biennis (evening primrose), oil, 6000mg (12x500mg, approx 9%
GLA, equivalent to 540mg GLA), capsules, oral.
Outcomes Pain VAS 0-100, well-being score, morning stiffness (minutes), Ritchie index, HAQ, intake of NSAIDs and
analgesics.
Notes Results favour intervention for morning stiffness, equivocal for all other outcomes.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double-blind, method not reported.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk Reported withdrawals.
Free of other bias? Unclear risk Placebo capsules contained olive oil and may not be inert. Reported ethics
committee approval.
Brzeski 1991 
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Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 16 weeks.
Participants Randomised n=182 (intervention n=89, control n=93), completed n=165 (intervention n=80, control
n=85). Age (yr): intervention m=45, control m=45. Inclusion: ACR criteria RA stage I-III.
Interventions RA-1, Ayurvedic formula, mixture of Withania somnifera, Boswellia serrata, Zingiberis officinale, Ciruma
longa, 444mg, (3x2), tablets, oral.
Outcomes 20% or 50% reduction in individual core set variables, patient global assessment, physician global as-
sessment, ARC20.
Notes Results equivocal.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Randomised to one of two groups using a computer generated random num-
ber sequence.
Allocation concealment? Low risk Adequate
Blinding? 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat and per protocol analyses.
Free of selective report-
ing?
Low risk Reported adverse events.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria. Reported ethics commit-
tee approval.
Chopra 2000 
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 6 weeks.
Participants Randomised n=61 (intervention n=31, control n=30). Dropouts not reported. Age (yr): intervention
m=42, control m=39. Inclusion: ACR criteria RA (any stage).
Interventions Tradename not provided, Tripterygium wilfordii (thunder god vine), tincture, 5-6 applications/day, topi-
cal.
Outcomes Modified ACR20, 42 tender joint count, 40 swollen joint count, grip strength kPa, morning stiffness
(hours), HAQ-DI, ESR, CRP, patient global, physician global.
Notes Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Cibere 2003 
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Adequate sequence gener-
ation?
Low risk Randomised to one of two groups using a computer generated random num-
ber sequence.
Allocation concealment? Low risk Adequate
Blinding? 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk Withdrawals not reported. Included intention-to-treat analyses.
Free of selective report-
ing?
Unclear risk Adverse events not reported. Confirmatory study.
Free of other bias? Unclear risk Diagnosis / assessment consistent with ACR criteria. Reanalysis of previous
study.
Cibere 2003  (Continued)
 
 
Methods Randomised, double blind, placebo-control, 2 parallel groups. Duration 4 weeks.
Participants Randomised n=31, completed n=29. Age range 20-79 yr. Inclusion: primary RA one/both knees, moder-
ate to very severe knee pain (scale of 0-4), at least 3 ACR criteria for classic, definite, or probable RA.
Interventions Zostrix, capsaicin 0.025% w v cream, topical, QID.
Outcomes Pain VAS 0-100, pain 0-4, physician global -1-3.
Notes Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell or packaging, but placebo validity and blinding may be
compromised by burning side effect of topical intervention.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals.
Free of selective report-
ing?
Unclear risk Variances reported as standard error of measurement (SEM). When converted
to standard deviation (SD), data are skewed, violating an assumption of the in-
ferential analyses. Reported adverse events.
Free of other bias? Unclear risk Diagnosis / assessment criteria for OA not specified.
Deal 1991 
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Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 12 months.
Participants Randomised n=37 (intervention n=20, control n=17), completed n=24 (intervention n=15, control n=9).
Age (yr): intervention m=61 sd=12, control m=59 sd=10. M:F=1:36. Inclusion: ACR criteria RA stage II or
III.
Interventions Phytodolor® N, mixture of ash bark, aspen leaf, aspen bark, golden rod herb, tincture, 3x30 drops, oral.
Concurrent intervention: diclofenac 25mg/d, oral.
Outcomes Joint stiffness, grip strength mmHg, Ritchie index.
Notes Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double blind, method not reported.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk Reported withdrawals.
Free of selective report-
ing?
Low risk Reported adverse events. Full data reported.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria.
Eberl 1988 
 
 
Methods Double-blind, randomised, controlled study. Duration 24 weeks.
Participants Randomized n=121 (Tripterygium wilfordii n=60; Sulfasalazine n=61), completed n=62 (Tripterygium wil-
fordii n=37, Sufasalazine n=25). Age (yr): Tripterygium wilfordii m=54 sd=11, Sufasalazine m=51 sd=12.
M:F = 1:1.2. Inclusion: ACR criteria RA, > 6 months.
Interventions Tripterygium wilfordii HF (TwHF) extract, 180 mg/day. Sufasalazine 2g/day.
Outcomes Primary end point: 20% improvement at 24 weeks, as defined by ACR criteria (ACR 20). Secondary end
points: efficacy of TwHF in achieving ACR 50 and ACR 70 responses at 24 weeks, the improvement in the
European League Against Rheumatism Disease Activity Score 28 (DAS 28) measure, and a change in the
Sharp–van der Heijde score of the hand and foot radiographs
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Goldbach-Mansky 2009 
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Adequate sequence gener-
ation?
Low risk Computer-generated, pseudo-random code (with random, permuted blocks)
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double blind. Patients are likely blinded, though this is not stat-
ed. "A rheumatologist or trained sta@ member masked to treatment allocation
assessed the patients."
Incomplete outcome data
addressed? 
All outcomes
Unclear risk There were a large number of drop-outs, all are accounted for with reasons
and they state that they used: "A protocol-specified, last-observation-car-
ried-forward approach for handling missing data..." It does appear that they
did an ITT analysis for several of the outcomes including the primary outcome
and report them in the text. All tables appear to be the per-protocol analyses.
Free of selective report-
ing?
Low risk  
Free of other bias? Unclear risk Baseline differences: Less women in the TwHF group (73% vs 87%); CRP ap-
peared to be slightly higher in the TwHF group (255.2 nmol/L vs 236.2 nmol/
L); Slightly higher radiographic score in the TwHF group (40.0 vs 34).There is no
discussion of differences in medications other than the interventions taking
throughout the study. These differences were not tested for significance.
Goldbach-Mansky 2009  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 13 weeks; 1 week washout, 12
weeks intervention.
Participants Randomised n=20 (intervention n=10, control n=10), completed n=18 (intervention n=9, control n=9).
Age: intervention m=50, control m=38. M:F=2:18. Inclusion: definite or classical RA, prepared to abstain
from NSAIDs for 13 weeks.
Interventions Tradename not provided, Oenothera biennis (evening primrose), oil, 20 mls (2x10ml, approx 9% GLA,
equivalent to 1800mg of GLA), oral.
Outcomes Pain VAS 0-100, joint score (swollen and tender joint counts), duration of morning stiffness, grip
strength.
Notes Results equivocal.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
Low risk Reported withdrawals.
Jantti 1989 
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All outcomes
Free of other bias? Unclear risk Placebo capsules contained olive oil and may not be inert. Diagnosis / assess-
ment criteria for OA not specified.
Jantti 1989  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 24 weeks.
Participants Randomised n=37 (intervention n=19, control n=18), completed n=27 (intervention n=14, control n=13).
Age: intervention m=58, control m=50. Inclusion: 18-80 yrs, ACR criteria RA stage I-III, using NSAIDs, not
using DMARDs.
Interventions Boracelle, Borago officinalis (borage seed), oil, 7.2ml (3x4x0.6ml, approx 23% GLA, equivalent to
1400mg GLA), capsules, oral.
Outcomes Pain VAS 0-100, pain 0-4, physician global 0-4, patient global 0-4, 68 tender joint count, 66 swollen joint
count, joint tenderness score 0-3, joint swelling score 0-3, duration of morning stiffness, vocational ac-
tivity score 0-3, grip strength mmHg.
Notes Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported. Baseline parameters com-
pared for significant differences.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double-blind, method not reported.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals.
Free of selective report-
ing?
Low risk Reported adverse events.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria.
Leventhal 1993 
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 24 weeks.
Participants Randomised n=34 (intervention n=14, control n=20), completed n=14 (intervention n=7, control n=7).
Age m=55. Inclusion: 18-80 yr, ACR criteria RA stage I-III, using NSAIDs, DMARDs stable for past 3 months.
Interventions Tradename not provided, Ribes nigrum (blackcurrant seed), oil, 10500mg (15x700mg, approx 19% GLA,
equivalent to 2000mg GLA), capsules, oral.
Leventhal 1994 
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Outcomes Pain VAS 0-100, pain 0-4, physician global 0-4 and VAS 0-100, patient global 0-4 and VAS 0-100, 68 ten-
der joint count, 66 swollen joint count, joint tenderness score 0-3, joint swelling score 0-3, morning stiff-
ness (minutes), vocational activity score 0-3, grip strength mmHg.
Notes Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported. Baseline parameters com-
pared for significant differences.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double-blind, method not reported.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat analyses.
Free of selective report-
ing?
Low risk Reported adverse events.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria.
Leventhal 1994  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 24 weeks.
Participants Randomised n=65 (intervention n=32, control n=33), completed n=58 (intervention n=28, control n=30).
Age: intervention m=50, control m=50. M:F=1:1. Inclusion: ACR criteria.
Interventions Ganoderma lucidum 4g per day together with San Miao San (a combination of Rhizoma atractylodis, Co-
tex phellodendri, and Radix achyranthes Bidentatae) 2.4 grams per day.
Outcomes Primary outcome: ACR 20% response; Secondary outcomes: changes in ACR components including ten-
der and swollen joint count, physician’s and patient’s global assessment, HAQ score, and ESR or CRP
level, total antioxidant power of plasma, plasma ascorbic acid concentration.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Computer generated list in blocks of 5
Allocation concealment? Low risk The list was generated at the Institute of Chinese Medicine, The Chinese Uni-
versity of Hong Kong. Study medications were dispensed as sealed packages in
consecutive numbers. A research nurse was responsible for dispensing study
medications. The investigators, research nurse, and participants were not
aware of the treatment assignments throughout the study. 
Li 2007 
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Treatment codes were only broken after completion of the study.
Blinding? 
All outcomes
Low risk The investigators, research nurse, and participants were not aware of the
treatment assignments throughout the study. Treatment codes were only bro-
ken after completion of the 
study.
Incomplete outcome data
addressed? 
All outcomes
High risk Three participants dropped out of the placebo group (2 due to inefficacy and 1
due to emigration); Four participants dropped out of the treatment group (all
due to inefficacy; three at week 8 and one at week 12)
Free of selective report-
ing?
Low risk All outcomes were reported
Free of other bias? High risk There are a selection of herbal medicines given in the active group. Also, par-
ticipants in the active group had slightly longer standing RA (9.3 years VS 7.8
years) and a larger number of participants in the active group were taking sul-
phasalazine (8 VS 4). None of these differences were tested for statistical differ-
ences.
Li 2007  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 4 weeks.
Participants Randomised n=7, completed n=5. Age: m=52, sd=4. Inclusion: ACR criteria RA.
Interventions Tradename not provided, capsaicin frutescens 0.075% wv cream, topical, QID.
Outcomes Pain VAS 0-100, morning stiffness (Landsbury 2 question method), HAQ, grip strength mmHg, swelling
(PIP, DIP circumference), tenderness (delorimeter).
Notes B:1, W:1. Placebo validity and blinding may be compromised by burning side effect of topical interven-
tion. Small sample size, underpowered study. Results equivocal.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method of randomisation incompletely reported.
Described as randomised according to a previously established randomisation
schedule.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell or packaging, but placebo validity and blinding possibly
compromised by burning side effect of topical intervention.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk Reported no withdrawals. Included per protocol analyses.
Free of selective report-
ing?
Unclear risk Variances reported as standard error of measurement (SEM). Reported ad-
verse events.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria.
McCarthy 1992 
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Methods Randomised, double blind, placebo control, non-intervention control, 3 parallel groups. Duration 2
weeks.
Participants Randomised n=15 (intervention n=5, placebo n=5, non-intervention n=5), completed n=15 (intervention
n=5, placebo n=5, non-intervention control n=5). Age range 23-76 yr; intervention m=62 sd=13, control
m=63 sd=16. M:F=9:6. Inclusion: ACR crtieria RA stage II or III.
Interventions PhytodolorRN, mixture of ash bark, aspen leaf, aspen bark, golden rod herb, tincture, 3x30 drops, oral.
Outcomes Diclofenac use, pain 0-3, joint swelling 0-3.
Notes Results equivocal. Groups dissimilar at baseline. Change (reduction) in diclofenac use and pain was
greatest in intervention group.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method of randomisation incompletely reported.
Described as randomised according to a previously established randomisation
schedule.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double-blind, method not reported. In other studies of Phytodo-
lor® N, active intervention and placebo not distinguished by look, taste, smell
or packaging. Non-intervention control group not blinded.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk Reported no withdrawals.
Free of selective report-
ing?
Low risk Full data reported.
Free of other bias? Unclear risk Diagnosis / assessment consistent with ACR criteria. Groups dissimilar at base-
line.
Meier 1987 
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 52 weeks; 24 weeks RCT, 28
weeks open trial.
Participants Randomised n=40 (intervention n=21, control n=19), completed n=38 (intervention n=20, control n=18).
Age: intervention m=53.1 sd=13.4, control m=54.9 sd=13.5. M:F intervention=20:1, control=15:4. Inclu-
sion: ACR criteria RA stage II or III, DMARDs (sulfasalazine or hydrochloroquine) for 6 months, dose sta-
ble for past 6 weeks.
Interventions Krallendorn, Uncaria tomentosa (cat's claw), aqueous dry extract of pentacylcic alkaloid chemotype,
60mg (3x20mg), capsules, oral.
Outcomes 66 swollen joint count, 68 tender joint count, Ritchie index, pain VAS 0-100, disease activity VAS 0-100,
morning stiffness 0-5, HAQ (baseline and week 24 only).
Mur 2002 
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Notes Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals.
Free of selective report-
ing?
Low risk Reported adverse events.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria.
Mur 2002  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 6 weeks.
Participants Randomised n=41 (intervention n=20, control n=21), completed n=40 (intervention n=20, control n=20).
Age range 28-65 yr. Inclusion: female, aged under 65 yr, classical or definite RA, poor symptomatic con-
trol.
Interventions Tanacetum parthenium (feverfew), (70-86mg), oral.
Outcomes Morning stiffness (minutes), inactivity stiffness, pain VAS 0-10, grip strength mmHg, Ritchie index, pa-
tient global, physician global.
Notes Results equivocal.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals.
Pattrick 1989 
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Free of selective report-
ing?
Low risk Reported adverse events.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria.
Pattrick 1989  (Continued)
 
 
Methods Randomised, double blind, placebo control, multi-centre trial, 2 parallel groups. Duration 12 weeks.
Participants Randomised n=78 (all centres). Data from one centre (Ratingen) available for analysis; randomised
n=37 (intervention n=18, control n=19), completed n=36 (intervention n=17, control n=19). Inclusion:
Active RA, at least one painful join, stable corticosteroids.
Interventions Boswellia serrata, 1200-3600mg, (3x400mg to 3x3x400mg), tablets, oral.
Outcomes Ritchie index, pain VAS 0-10, NSAID consumption, patient global VAS 0-10.
Notes Results equivocal.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals.
Free of selective report-
ing?
Low risk Reported adverse events. Non-normal data reported as median and range.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria. Reported ethics commit-
tee approval.
Sandler 1998 
 
 
Methods Randomised, double blind, active control (celecoxib), 2 parallel group, multicentre trial. Duration 6
weeks.
Participants Randomised n=183 (intervention n=91, control n=92), completed n=168 (intervention n=84, control
n=84). Age (yr): intervention m=52.1 sd=12.6, control m=51.7 sd=10.9. M:F=1:8. Inclusion: ACR criteria RA
stage I, II or III, disease duration >3 months, stable medications, pain (VAS 0-100) increase of 10+mm,
and 6+ tender joints, and 3+ swollen joints after NSAID washout.
Interventions SKI306X, extract mixture of Clematis mandshurica, Prunella vulgaris, Trichosanthes kirilowii, 600mg
(3x200mg), tablets, oral.
Song 2007 
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Outcomes Pain (VAS 0-100), rescue medication use (acetaminophen), ACR20.
Notes Results indicate that intervention is not inferior to active control.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Randomised to one of two groups using a computer generated random num-
ber sequence. Baseline parameters compared for significant differences.
Allocation concealment? Low risk Adequate
Blinding? 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat and per protocol analyses.
Free of selective report-
ing?
Low risk Reported adverse events. Confirmatory study.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria. Reported ethics commit-
tee approval.
Song 2007  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 groups crossover study. Duration 16 weeks: 12 weeks in-
tervention 1st arm, 4 weeks intervention 2nd arm.
Participants Randomised n=70, completed first arm n=58. Age: m=47 yr. Inclusion: classic or definite RA of at least 6
months duration with poor response to NSAIDs for at least 2 months.
Interventions Tripterygium wilfordii hook F (thunder god vine), ethanolic extract, 60mg, capsules, oral.
Outcomes Joint tenderness and swelling, grip strength, 15 metre walking time, morning stiffness, physician glob-
al, patient global.
Notes Results favour intervention for short-term use (12 weeks), with cautions regarding adverse events.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double-blind, method not reported.
Incomplete outcome data
addressed? 
Low risk Reported withdrawals.
Tao 1989 
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All outcomes
Free of selective report-
ing?
Low risk Reported adverse events.
Free of other bias? Low risk Reported ethics committee approval.
Tao 1989  (Continued)
 
 
Methods Randomised, double blind, placebo control, 3 parallel groups. Duration 20 weeks.
Participants Randomised n=35 (low dose n=12, high dose n=11, control n=12), completed 4 weeks n=32, completed
n=21. Age: low dose m=54 sd=12, high dose m=57 sd=8, control m=51 sd=12. Inclusion: ACR criteria RA
stage II-IV, for at least 1 year, active disease, 2+ swollen joints, and 2 of 6+ tender joints, morning stiff-
ness >30min, ESR >28mm/h.
Interventions Tripterygium wilfordii hook F (thunder god vine), ethanolic extract, low dose=180mg; high dose=360mg,
capsules, oral.
Outcomes ACR20, ACR50, ACR70, ESR, CRP, RF.
Notes Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported. Baseline parameters com-
pared for significant differences.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging.
Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat analyses.
Free of selective report-
ing?
Low risk Reported adverse events.
Free of other bias? Low risk Diagnosis / assessment consistent with ACR criteria. Reported ethics commit-
tee approval.
Tao 2002 
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 6 weeks.
Participants Randomised n=50. Withdrawals not reported. Age: RA group m=40, health controls m=20 yr. Inclusion:
definite RA, receiving only NSAIDs.
Watson 1993 
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Interventions Tradename not provided, Ribes nigrum, (blackcurrant seed), oil, 3000mg (6x500mg, approx 19% GLA,
equivalent to 525mg GLA), capsules, oral.
Outcomes Morning stiffness, grip strength, Ritchie index, pain score, patient global.
Notes Results equivocal.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double-blind, method not reported.
Incomplete outcome data
addressed? 
All outcomes
High risk Withdrawals not reported.
Free of selective report-
ing?
High risk Adverse events not reported.
Free of other bias? High risk Data for clinical outcomes not reported.
Watson 1993  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 6 months (followed by 6 month
single-blind phase, followed by 3 month placebo phase).
Participants Randomised n=56, completed n=41. Age: m=56 yr. Inclusion: ACR criteria RA stage I-III, 1st line treat-
ment stable for past 1 month, 2nd line treatment stable for past 3 months.
Interventions GLA-70, Borago officinalis (borage seed), oil, 4ml (8x0.5ml, approx 70% GLA, equivalent to 2800mg GLA),
capsules, oral.
Outcomes Pain VAS 0-100, pain 0-4, physician global, patient global, joint swelling and tenderness, morning stiff-
ness, grip strength, health assessment questionnaire, ACR20 (6 and 12 month follow up).
Notes Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Described as randomised, method not reported. Baseline parameters com-
pared for significant differences.
Allocation concealment? Unclear risk Unclear
Blinding? 
All outcomes
Unclear risk Described as double blind, method not reported.
Zurier 1996 
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Incomplete outcome data
addressed? 
All outcomes
Low risk Reported withdrawals.
Free of selective report-
ing?
Unclear risk After communication with author, unable to confirm SD for morning stiffness
in GLA group (table 2) therefore these data excluded from analysis.
Free of other bias? Unclear risk Placebo capsules contained sunflower oil and may not be inert. Diagnosis / as-
sessment consistent with ACR criteria.
Zurier 1996  (Continued)
Unless otherwise stated, all oral medications are reported as total daily doses, which may have been administered in single or divided
doses. * Indicates that the trade name was not provided in the manuscript, but has been determined through communication with the
manufacturing company noted in the acknowledgements.
ARA: American Rheumatism Association
ACR: American College of Rheumatology
EULAR: European league Against Rheumatism
Allocation concealment may be listed as "unclear" if: (a) the authors reported adherence to the ICH Good Clinical Practice (GCP) guidelines
did not describe the method of allocation concealment used, or (b) the reviewers were unable to agree upon the adequacy of allocation
concealment as reported.
Unless subscales are named, outcome measures (eg: HAQ, SF-36, ACR20) were used in entirety. Unless specified, all measures were used,
scaled, and scored to ACR/EULAR standards.
ACR core set of disease activity measures comprises tender joint count, swollen joint count, patient's assessment of pain, patient's and
physician's global assessment of disease activity, patient's assessment of physical function (global assessment or HAQ-DI score), and
laboratory investigations of one acute-phase reactant (ESR or C-reactive protein). ACR20 is defined as 20% improvements in tender joint
count, swollen joint count, and three of the other disease activity measures. ACR50 and ACR70 are similarly defined, but at 50% and 70%
thresholds.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Anonymous 1993 Discussion paper.
Biswas 1997 Not placebo controlled.
Borigini 1996 Not randomised controlled trial.
Chrubasik 1998 Review paper.
Darlington 1987 Not placebo controlled.
DeLuca 1995 Review paper.
Dharmananda 1985 Discussion paper.
Falch 1997 Discussion paper.
Gendo 1997 Discussion paper.
Grahame 1981 Not randomised controlled trial.
Guo 1986 Not randomised controlled trial.
Hansen 1983 Not randomised controlled trial.
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Study Reason for exclusion
Hanyu 1989 Not randomised controlled trial.
Huber 1991 RA subgroup not distinguishable.
Jacobs 1991 Not a herbal intervention.
Jantti 1989b No clinical outcomes reported.
Kou 1997 Case series, not a randomised controlled trial.
Larsen 1989 Not truly herbal intervention.
Linsheng 1997 Not randomised controlled trial.
Lipsky 1997 Review paper.
Loew 1996 Not a randomised controlled trial. Primary measures not consistent with the topic of this review.
Matsuta 1992 Discussion paper.
Mills 1996 RA subgroup not distinguishable.
Ohkaya 1988 Abstract only. Full text unavailable.
Ohkaya 1989 Abstract only. Full text unavailable.
Ramakrishanamacharya Not randomised controlled trial.
Ramm 1996 Not randomised controlled trial.
Reuss 1981 Discussion paper.
Sagar 1988 Not randomised controlled trial.
Saley 1987 Not randomised controlled trial.
Srivastava 1989 Not randomised controlled trial.
Tao 1987 Not randomised controlled trial.
Vyas 1987 Not randomised controlled trial.
Wang 1985 Not randomised controlled trial.
Xu 1996 Not placebo controlled.
Yan 1985 Case series, not a randomised controlled trial.
Zell 1993 Not randomised controlled trial.
 
Characteristics of ongoing studies [ordered by study ID]
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Trial name or title A clinical trial to study the effects of a herbal drug Qurs Mufasil in patients with joint pain (Arthritis)
Methods Randomized, parallel group, placebo controlled trial
Participants Patients of 20-70 years of age fulfilling the criteria of American College of Rheumatology (ACR) for
the diagnosis of Rheumatoid Arthritis, who had never received disease modifying anti/Rheumatoid
Drugs (DMARDs). Presence of active disease as defined by the presence of >, 6 tender joints and >; 6
swollen joints.
Interventions Qurs Mufasil:1000 mg daily for 3 months
Placebo:1000 mg twice daily for 3 months
Outcomes Reduction in Swollen Joint Count,Tender Joint Count, Intensity of Pain-VAS (0-100), Morning Stiff-
ness, ESR and CRP Timepoint:4,8,12 weeks;
Improvement in quality of life as assessed by Health Assessment Questionnaire (HAQ) Time Point: 3
months
Starting date 01-03-2003
Contact information Yasmeen Shamsi
Majeedia Hospital, Jamia Hamdard, 110062 New Delhi, India
Email: yasmeen.ijum@gmail.com
Notes Recruitment complete; http://apps.who.int/trialsearch/Trial.aspx?TrialID=CTRI/2009/091/000746
Shamsi 2009 
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Gamma-linolenic acid versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 4   Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 At 12 weeks- VAS score 1 18 Mean Difference (IV, Random, 95% CI) 6.00 [-16.36, 28.36]
1.2 At 6 months- change from
baseline
3 82 Mean Difference (IV, Random, 95% CI) -32.83 [-56.25, -9.42]
2 Morning stiffness (minutes) 4   Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 At 12 weeks- minutes 1 18 Mean Difference (IV, Random, 95% CI) -5.0 [-41.68, 31.68]
2.2 At 6 months- change from
baseline
3 82 Mean Difference (IV, Random, 95% CI) -55.07 [-76.87, -33.27]
3 68 tender joint count per-
centage change from base-
line
3 82 Mean Difference (IV, Random, 95% CI) -53.80 [-95.61, -12.00]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 66 swollen joint count per-
centage change from base-
line
3 82 Mean Difference (IV, Fixed, 95% CI) -14.43 [-31.43, 2.56]
5 Joint tenderness (0 to 3)
percentage change from
baseline
3 82 Mean Difference (IV, Random, 95% CI) -56.64 [-98.10, -15.17]
6 Joint swelling (0 to 3) per-
centage change from base-
line
3 82 Mean Difference (IV, Random, 95% CI) -24.02 [-70.80, 22.76]
7 HAQ disability score per-
centage change from base-
line
1   Mean Difference (IV, Random, 95% CI) Totals not selected
8 Patient global (0 to 4) per-
centage change from base-
line
3 82 Mean Difference (IV, Random, 95% CI) -20.87 [-39.43, -2.31]
9 Physician global (0 to 4)
percentage change from
baseline
3 82 Mean Difference (IV, Random, 95% CI) -21.28 [-70.52, 27.95]
10 Participants (n) reported
reduced NSAID use
2   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 At 6 months 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 At 12 months 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Participants (n) reported
adverse events
2 61 Risk Ratio (M-H, Random, 95% CI) 4.24 [0.78, 22.99]
11.1 GLA 540mg 1 34 Risk Ratio (M-H, Random, 95% CI) 5.59 [0.29, 108.38]
11.2 GLA 1400mg+ 1 27 Risk Ratio (M-H, Random, 95% CI) 3.71 [0.47, 29.06]
12 Participants (n) withdrawn
due to worsening disease
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 1.1.   Comparison 1 Gamma-linolenic acid versus placebo, Outcome 1 Pain VAS 0-100.
Study or subgroup Favours GLA Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.1.1 At 12 weeks- VAS score  
Jantti 1989 9 29.3 (25.7) 9 23.3 (22.6) 100% 6[-16.36,28.36]
Subtotal *** 9   9   100% 6[-16.36,28.36]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.53(P=0.6)  
Favours GLA 200100-200 -100 0 Favours placebo
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Study or subgroup Favours GLA Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
1.1.2 At 6 months- change from baseline  
Leventhal 1993 14 -15 (29) 13 60 (140) 9.1% -75[-152.6,2.6]
Leventhal 1994 7 -33 (39) 7 -4 (40) 32.01% -29[-70.39,12.39]
Zurier 1996 22 -26.8 (58.5) 19 1.6 (40.6) 58.89% -28.4[-58.91,2.11]
Subtotal *** 43   39   100% -32.83[-56.25,-9.42]
Heterogeneity: Tau2=0; Chi2=1.25, df=2(P=0.54); I2=0%  
Test for overall effect: Z=2.75(P=0.01)  
Favours GLA 200100-200 -100 0 Favours placebo
 
 
Analysis 1.2.   Comparison 1 Gamma-linolenic acid versus placebo, Outcome 2 Morning sti>ness (minutes).
Study or subgroup GLA Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.2.1 At 12 weeks- minutes  
Jantti 1989 9 35 (39.7) 9 40 (39.7) 100% -5[-41.68,31.68]
Subtotal *** 9   9   100% -5[-41.68,31.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.27(P=0.79)  
   
1.2.2 At 6 months- change from baseline  
Leventhal 1993 14 -33 (72) 13 4 (69) 13.74% -37[-90.19,16.19]
Leventhal 1994 7 -21 (69) 7 0 (45) 10.92% -21[-82.02,40.02]
Zurier 1996 22 -55.4 (1) 19 7.9 (1.4) 75.34% -63.3[-64.05,-62.55]
Subtotal *** 43   39   100% -55.07[-76.87,-33.27]
Heterogeneity: Tau2=164.09; Chi2=2.78, df=2(P=0.25); I2=28.16%  
Test for overall effect: Z=4.95(P<0.0001)  
Favours GLA 10050-100 -50 0 Favours placebo
 
 
Analysis 1.3.   Comparison 1 Gamma-linolenic acid versus placebo,
Outcome 3 68 tender joint count percentage change from baseline.
Study or subgroup GLA Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Leventhal 1993 14 -36 (43) 13 30 (75) 30.25% -66[-112.58,-19.42]
Leventhal 1994 7 -55 (35) 7 34 (64) 26.77% -89[-143.04,-34.96]
Zurier 1996 22 -35.2 (32.5) 19 -11.9 (36.8) 42.98% -23.3[-44.71,-1.89]
   
Total *** 43   39   100% -53.8[-95.61,-12]
Heterogeneity: Tau2=938.99; Chi2=6.62, df=2(P=0.04); I2=69.78%  
Test for overall effect: Z=2.52(P=0.01)  
Favours GLA 10050-100 -50 0 Favours placebo
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Analysis 1.4.   Comparison 1 Gamma-linolenic acid versus placebo,
Outcome 4 66 swollen joint count percentage change from baseline.
Study or subgroup GLA Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Leventhal 1993 14 -28 (53) 13 48 (161) 3.43% -76[-167.82,15.82]
Leventhal 1994 7 42 (109) 7 34 (142) 1.64% 8[-124.61,140.61]
Zurier 1996 22 -20.9 (34.3) 19 -8.3 (22.1) 94.93% -12.6[-30.04,4.84]
   
Total *** 43   39   100% -14.43[-31.43,2.56]
Heterogeneity: Tau2=0; Chi2=1.88, df=2(P=0.39); I2=0%  
Test for overall effect: Z=1.66(P=0.1)  
Favours GLA 10050-100 -50 0 Favours placebo
 
 
Analysis 1.5.   Comparison 1 Gamma-linolenic acid versus placebo,
Outcome 5 Joint tenderness (0 to 3) percentage change from baseline.
Study or subgroup GLA Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Leventhal 1993 14 -45 (38) 13 55 (109) 23.89% -100[-162.51,-37.49]
Leventhal 1994 7 -53 (42) 7 12 (44) 32.32% -65[-110.06,-19.94]
Zurier 1996 22 -37.5 (35.6) 19 -10.7 (45.4) 43.78% -26.8[-52.06,-1.54]
   
Total *** 43   39   100% -56.64[-98.1,-15.17]
Heterogeneity: Tau2=856.21; Chi2=5.69, df=2(P=0.06); I2=64.85%  
Test for overall effect: Z=2.68(P=0.01)  
Favours GLA 10050-100 -50 0 Favours placebo
 
 
Analysis 1.6.   Comparison 1 Gamma-linolenic acid versus placebo,
Outcome 6 Joint swelling (0 to 3) percentage change from baseline.
Study or subgroup GLA Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Leventhal 1993 14 -41 (48) 13 40 (132) 24.43% -81[-157.03,-4.97]
Leventhal 1994 7 19 (86) 7 18 (130) 13.25% 1[-114.47,116.47]
Zurier 1996 22 -23.1 (31.2) 19 -16.1 (28.5) 62.32% -7[-25.28,11.28]
   
Total *** 43   39   100% -24.02[-70.8,22.76]
Heterogeneity: Tau2=827.17; Chi2=3.48, df=2(P=0.18); I2=42.54%  
Test for overall effect: Z=1.01(P=0.31)  
Favours GLA 10050-100 -50 0 Favours placebo
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Analysis 1.7.   Comparison 1 Gamma-linolenic acid versus placebo,
Outcome 7 HAQ disability score percentage change from baseline.
Study or subgroup GLA Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Zurier 1996 22 -11 (19) 19 4.8 (17.9) -15.75[-27.06,-4.44]
Favours GLA 10050-100 -50 0 Favours placebo
 
 
Analysis 1.8.   Comparison 1 Gamma-linolenic acid versus placebo,
Outcome 8 Patient global (0 to 4) percentage change from baseline.
Study or subgroup GLA Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Leventhal 1993 14 -21 (33) 13 30 (85) 14.16% -51[-100.33,-1.67]
Leventhal 1994 7 -1 (38) 7 24 (61) 12.16% -25[-78.24,28.24]
Zurier 1996 22 -18.9 (35.6) 19 -4.5 (34.9) 73.69% -14.4[-36.02,7.22]
   
Total *** 43   39   100% -20.87[-39.43,-2.31]
Heterogeneity: Tau2=0; Chi2=1.8, df=2(P=0.41); I2=0%  
Test for overall effect: Z=2.2(P=0.03)  
Favours GLA 10050-100 -50 0 Favours placebo
 
 
Analysis 1.9.   Comparison 1 Gamma-linolenic acid versus placebo,
Outcome 9 Physician global (0 to 4) percentage change from baseline.
Study or subgroup GLA Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Leventhal 1993 14 -33 (28) 13 43 (81) 30.18% -76[-122.41,-29.59]
Leventhal 1994 7 0 (56) 7 7 (19) 31.09% -7[-50.81,36.81]
Zurier 1996 22 2.1 (34.6) 19 -7.8 (29.3) 38.72% 9.9[-9.66,29.46]
   
Total *** 43   39   100% -21.28[-70.52,27.95]
Heterogeneity: Tau2=1529.99; Chi2=11.2, df=2(P=0); I2=82.15%  
Test for overall effect: Z=0.85(P=0.4)  
Favours GLA 10050-100 -50 0 Favours placebo
 
 
Analysis 1.10.   Comparison 1 Gamma-linolenic acid versus
placebo, Outcome 10 Participants (n) reported reduced NSAID use.
Study or subgroup GLA Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
1.10.1 At 6 months  
Brzeski 1991 3/13 3/17 1.31[0.31,5.45]
   
1.10.2 At 12 months  
Belch 1988 11/15 5/15 2.2[1.01,4.79]
Placebo 100.1 50.2 20.5 1 GLA
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Analysis 1.11.   Comparison 1 Gamma-linolenic acid versus
placebo, Outcome 11 Participants (n) reported adverse events.
Study or subgroup GLA Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.11.1 GLA 540mg  
Belch 1988 2/16 0/18 32.5% 5.59[0.29,108.38]
Subtotal (95% CI) 16 18 32.5% 5.59[0.29,108.38]
Total events: 2 (GLA), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.14(P=0.26)  
   
1.11.2 GLA 1400mg+  
Leventhal 1993 4/14 1/13 67.5% 3.71[0.47,29.06]
Subtotal (95% CI) 14 13 67.5% 3.71[0.47,29.06]
Total events: 4 (GLA), 1 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
Total (95% CI) 30 31 100% 4.24[0.78,22.99]
Total events: 6 (GLA), 1 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%  
Test for overall effect: Z=1.68(P=0.09)  
Test for subgroup differences: Not applicable  
Favours GLA 2000.005 100.1 1 Favours Placebo
 
 
Analysis 1.12.   Comparison 1 Gamma-linolenic acid versus placebo,
Outcome 12 Participants (n) withdrawn due to worsening disease.
Study or subgroup GLA Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Belch 1988 1/16 10/18 0.11[0.02,0.78]
Placebo 1000.01 100.1 1 GLA
 
 
Comparison 2.   Tripterygium wilfordii Hook F 60 mg versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Joint tenderness (0 to 3) 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
2 60 swollen joint count 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
3 Morning stiffness (hours) 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 Grip strength (mmHg) 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
5 15 metre walking time (seconds) 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
 
 
Analysis 2.1.   Comparison 2 Tripterygium wilfordii Hook F 60 mg versus placebo, Outcome 1 Joint tenderness (0 to 3).
Study or subgroup TwHF 60 mg Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Tao 1989 27 7.9 (6.9) 31 21.9 (12.2) -14[-19.02,-8.98]
Favours TWHF 2010-20 -10 0 Favours placebo
 
 
Analysis 2.2.   Comparison 2 Tripterygium wilfordii Hook F 60 mg versus placebo, Outcome 2 60 swollen joint count.
Study or subgroup TwHF 60 mg Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Tao 1989 27 4.3 (3.2) 31 7.4 (6) -3.1[-5.53,-0.67]
Favours TWHF 2010-20 -10 0 Favours placebo
 
 
Analysis 2.3.   Comparison 2 Tripterygium wilfordii Hook F
60 mg versus placebo, Outcome 3 Morning sti>ness (hours).
Study or subgroup TwHF 60 mg Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Tao 1989 27 0.9 (1.2) 31 2.3 (7.8) -1.4[-4.18,1.38]
Favours TWHF 52.5-5 -2.5 0 Favours placebo
 
 
Analysis 2.4.   Comparison 2 Tripterygium wilfordii Hook F 60 mg versus placebo, Outcome 4 Grip strength (mmHg).
Study or subgroup TwHF 60 mg Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Tao 1989 27 84.4 (39) 31 81.2 (51) 3.2[-20.01,26.41]
Favours placebo 2010-20 -10 0 Favours TWHF
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Analysis 2.5.   Comparison 2 Tripterygium wilfordii Hook F 60 mg
versus placebo, Outcome 5 15 metre walking time (seconds).
Study or subgroup TwHF 60 mg Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Tao 1989 27 20.6 (7.7) 31 31 (32.1) -10.4[-22.07,1.27]
Favours TWHF 2010-20 -10 0 Favours placebo
 
 
Comparison 3.   Tripterygium wilfordii Hook F 180 mg versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 ACR20 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 ACR50 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Participants (n) reported adverse
events
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3 Tripterygium wilfordii Hook F 180 mg versus placebo, Outcome 1 ACR20 responders.
Study or subgroup TwHF 180 mg Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Tao 2002 4/12 0/12 9[0.54,150.81]
Favours placebo 2000.005 100.1 1 Favours TWHF
 
 
Analysis 3.2.   Comparison 3 Tripterygium wilfordii Hook F 180 mg versus placebo, Outcome 2 ACR50 responders.
Study or subgroup TwHF 180 mg Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Tao 2002 1/12 0/12 3[0.13,67.06]
Favours placebo 1000.01 100.1 1 Favours TWHF
 
 
Analysis 3.3.   Comparison 3 Tripterygium wilfordii Hook F 180 mg
versus placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup TwHF 180 mg Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Tao 2002 6/12 4/12 1.5[0.56,4]
Favours TWHF 500.02 100.1 1 Favours placebo
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Comparison 4.   Triptrygium wilfordii Hook F 360 mg versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 ACR20 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 ACR50 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Participants (n) reported adverse
events
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 4.1.   Comparison 4 Triptrygium wilfordii Hook F 360 mg versus placebo, Outcome 1 ACR20 responders.
Study or subgroup TwHF 360 mg Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Tao 2002 8/11 0/12 18.42[1.19,285.82]
Favours placebo 2000.005 100.1 1 Favours TWHF
 
 
Analysis 4.2.   Comparison 4 Triptrygium wilfordii Hook F 360 mg versus placebo, Outcome 2 ACR50 responders.
Study or subgroup TwHF 360 mg Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Tao 2002 5/11 0/12 11.92[0.73,193.38]
Favours placebo 2000.005 100.1 1 Favours TWHF
 
 
Analysis 4.3.   Comparison 4 Triptrygium wilfordii Hook F 360 mg
versus placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup TwHF 360 mg Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Tao 2002 5/11 4/12 1.36[0.49,3.82]
Favours TWHF 100.1 50.2 20.5 1 Favours placebo
 
 
Comparison 5.   Tripterygium wilfordii Hook F 180 mg versus sulfasalazine
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 ACR20 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 ACR50 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Improvement more than 0.3
units on HAQ
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Participants (n) reported ad-
verse events
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Participants (n) withdrawn
due to adverse events
1 121 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.19, 0.94]
 
 
Analysis 5.1.   Comparison 5 Tripterygium wilfordii Hook F
180 mg versus sulfasalazine, Outcome 1 ACR20 responders.
Study or subgroup TwHF 180 mg Sulfasalazine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Goldbach-Mansky 2009 39/60 20/61 1.98[1.32,2.97]
Favours sulfasalazine 50.2 20.5 1 Favours TWHF
 
 
Analysis 5.2.   Comparison 5 Tripterygium wilfordii Hook F
180 mg versus sulfasalazine, Outcome 2 ACR50 responders.
Study or subgroup TwHF 180 mg Sulfasalazine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Goldbach-Mansky 2009 20/60 1/61 20.33[2.82,146.75]
Favours sulfasalazine 2000.005 100.1 1 Favours TWHF
 
 
Analysis 5.3.   Comparison 5 Tripterygium wilfordii Hook F 180 mg versus
sulfasalazine, Outcome 3 Improvement more than 0.3 units on HAQ.
Study or subgroup TwHF 180 mg Sulfasalazine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Goldbach-Mansky 2009 21/60 7/61 3.05[1.4,6.64]
Favours sulfasalazine 1000.01 100.1 1 Favours TWHF
 
 
Analysis 5.4.   Comparison 5 Tripterygium wilfordii Hook F 180 mg versus
sulfasalazine, Outcome 4 Participants (n) reported adverse events.
Study or subgroup TwHF 180 mg Sulfasalazine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Goldbach-Mansky 2009 53/60 55/61 0.98[0.87,1.11]
Favours TWHF 20.5 1.50.7 1 Favours sulfasalazine
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Analysis 5.5.   Comparison 5 Tripterygium wilfordii Hook F 180 mg versus
sulfasalazine, Outcome 5 Participants (n) withdrawn due to adverse events.
Study or subgroup TwHF 180 mg Sulfasalazine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Goldbach-Mansky 2009 7/60 17/61 100% 0.42[0.19,0.94]
   
Total (95% CI) 60 61 100% 0.42[0.19,0.94]
Total events: 7 (TwHF 180 mg), 17 (Sulfasalazine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.12(P=0.03)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Comparison 6.   Phytodolor N versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain (0 to 3) at 2 weeks 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
2 Joint swelling (0 to 3) at 2 weeks 1   Mean Difference (IV, Random,
95% CI)
Subtotals only
3 Morning stiffness (minutes) at 12 months 1   Mean Difference (IV, Random,
95% CI)
Subtotals only
4 Ritchie index at 12 months 1   Mean Difference (IV, Random,
95% CI)
Subtotals only
5 Cumulative NSAID use (diclofenac) 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
5.1 At 1 month (tablets) 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
5.2 At 12 months (tablets) 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
 
 
Analysis 6.1.   Comparison 6 Phytodolor N versus placebo, Outcome 1 Pain (0 to 3) at 2 weeks.
Study or subgroup Phytodolor N Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Meier 1987 5 1.2 (0.4) 5 1.1 (0.7) 0.1[-0.61,0.81]
Favours Phytodolor N 10.5-1 -0.5 0 Favours placebo
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Analysis 6.2.   Comparison 6 Phytodolor N versus placebo, Outcome 2 Joint swelling (0 to 3) at 2 weeks.
Study or subgroup Phytodolor N Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Meier 1987 5 1 (0.9) 5 0.6 (0.5) 0% 0.4[-0.5,1.3]
Favours Phytodolor N 42-4 -2 0 Favours placebo
 
 
Analysis 6.3.   Comparison 6 Phytodolor N versus placebo, Outcome 3 Morning sti>ness (minutes) at 12 months.
Study or subgroup Phytodolor N Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Eberl 1988 20 54.5 (54.6) 16 30.6 (29.2) 0% 23.9[-3.98,51.78]
Favours Phytodolor N 10050-100 -50 0 Favours placebo
 
 
Analysis 6.4.   Comparison 6 Phytodolor N versus placebo, Outcome 4 Ritchie index at 12 months.
Study or subgroup Phytodolor N Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Eberl 1988 20 19.1 (3) 16 22.1 (5.3) 0% -3[-5.91,-0.09]
Favours Phytodolor N 105-10 -5 0 Favours placebo
 
 
Analysis 6.5.   Comparison 6 Phytodolor N versus placebo, Outcome 5 Cumulative NSAID use (diclofenac).
Study or subgroup Phytodolor N Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
6.5.1 At 1 month (tablets)  
Eberl 1988 20 116.8 (42.6) 16 106 (36.4) 10.8[-15.02,36.62]
   
6.5.2 At 12 months (tablets)  
Eberl 1988 20 1268.1 (507.4) 16 1251.3 (455.5) 16.8[-298.26,331.86]
Favours Phytodolor N 500250-500 -250 0 Favours placebo
 
 
Comparison 7.   SKI306X versus celecoxib
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from base-
line
1   Mean Difference (IV, Random, 95%
CI)
Totals not selected
1.1 At 3 weeks 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
1.2 At 6 weeks 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 ACR20 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 At 3 weeks 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 At 6 weeks 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Participants (n) reported adverse
events
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 7.1.   Comparison 7 SKI306X versus celecoxib, Outcome 1 Pain VAS 0-100 change from baseline.
Study or subgroup SKI306X Celecoxib Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
7.1.1 At 3 weeks  
Song 2007 87 13.6 (16.6) 87 14.5 (15.9) -0.81[-5.64,4.02]
   
7.1.2 At 6 weeks  
Song 2007 87 18.8 (20.8) 87 17.9 (19.1) 0.94[-4.99,6.87]
Favours SKI036X 105-10 -5 0 Favours celecoxib
 
 
Analysis 7.2.   Comparison 7 SKI306X versus celecoxib, Outcome 2 ACR20 responders.
Study or subgroup SKI306X Celecoxib Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
7.2.1 At 3 weeks  
Song 2007 16/87 24/87 0.67[0.38,1.17]
   
7.2.2 At 6 weeks  
Song 2007 29/87 29/87 1[0.66,1.52]
Favours celecoxib 100.1 50.2 20.5 1 Favours SKI306X
 
 
Analysis 7.3.   Comparison 7 SKI306X versus celecoxib, Outcome 3 Participants (n) reported adverse events.
Study or subgroup SKI306X Celecoxib Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Song 2007 38/91 36/92 1.07[0.75,1.52]
Favours SKI306X 100.1 50.2 20.5 1 Favours celecoxib
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Comparison 8.   Salix purpurea x daphnoides (willow bark) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from base-
line
1   Mean Difference (IV, Random, 95% CI) Totals not selected
2 28 tender joint count change from
baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 28 swollen joint count change
from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
4 Patient assessment of efficacy VAS
0-100 change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
5 Physician assessment of effiacy
VAS 0-100 change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
6 ACR20 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 HAQ disability index change from
baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
8 SF-36 physical component sum-
mary score change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
9 SF-36 mental component summa-
ry score change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
 
 
Analysis 8.1.   Comparison 8 Salix purpurea x daphnoides (willow bark)
versus placebo, Outcome 1 Pain VAS 0-100 change from baseline.
Study or subgroup Willow bark Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Biegert 2004 13 -8 (24) 13 -2 (27) -6[-25.64,13.64]
Favours willow bark 10050-100 -50 0 Favours placebo
 
 
Analysis 8.2.   Comparison 8 Salix purpurea x daphnoides (willow bark)
versus placebo, Outcome 2 28 tender joint count change from baseline.
Study or subgroup Willow bark Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Biegert 2004 13 -1 (6.7) 13 -2.1 (2.8) 1.1[-2.85,5.05]
Favours willow bark 105-10 -5 0 Favours placebo
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Analysis 8.3.   Comparison 8 Salix purpurea x daphnoides (willow bark)
versus placebo, Outcome 3 28 swollen joint count change from baseline.
Study or subgroup Willow bark Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Biegert 2004 13 -0.7 (7.4) 13 -1.2 (3.2) 0.5[-3.88,4.88]
Favours willow bark 105-10 -5 0 Favours placebo
 
 
Analysis 8.4.   Comparison 8 Salix purpurea x daphnoides (willow bark) versus
placebo, Outcome 4 Patient assessment of e>icacy VAS 0-100 change from baseline.
Study or subgroup Willow bark Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Biegert 2004 13 3 (17) 13 2 (25) 1[-15.43,17.43]
Favours willow bark 2010-20 -10 0 Favours placebo
 
 
Analysis 8.5.   Comparison 8 Salix purpurea x daphnoides (willow bark) versus
placebo, Outcome 5 Physician assessment of e>iacy VAS 0-100 change from baseline.
Study or subgroup Willow bark Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Biegert 2004 13 8 (23) 13 -2 (16) 10[-5.23,25.23]
Favours willow bark 5025-50 -25 0 Favours placebo
 
 
Analysis 8.6.   Comparison 8 Salix purpurea x daphnoides
(willow bark) versus placebo, Outcome 6 ACR20 responders.
Study or subgroup Willow bark Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Biegert 2004 2/13 1/13 2[0.21,19.44]
Favours placebo 200.05 50.2 1 Favours willow bark
 
 
Analysis 8.7.   Comparison 8 Salix purpurea x daphnoides (willow bark)
versus placebo, Outcome 7 HAQ disability index change from baseline.
Study or subgroup Willow bark Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Biegert 2004 13 0 (0.3) 13 0.1 (0.2) -0.1[-0.3,0.1]
Favours willow bark 0.50.25-0.5 -0.25 0 Favours placebo
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Analysis 8.8.   Comparison 8 Salix purpurea x daphnoides (willow bark) versus
placebo, Outcome 8 SF-36 physical component summary score change from baseline.
Study or subgroup Willow bark Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Biegert 2004 13 2.6 (5.4) 13 -1.3 (5.8) 3.9[-0.41,8.21]
Favours placebo 105-10 -5 0 Favours willow bark
 
 
Analysis 8.9.   Comparison 8 Salix purpurea x daphnoides (willow bark) versus
placebo, Outcome 9 SF-36 mental component summary score change from baseline.
Study or subgroup Willow bark Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Biegert 2004 13 0.6 (9) 13 -3.3 (4.7) 3.9[-1.62,9.42]
Favours placebo 105-10 -5 0 Favours willow bark
 
 
Comparison 9.   Feverfew versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Grip strength (mmHg) at 6 weeks 1   Mean Difference (IV, Random, 95% CI) Totals not selected
2 Participants (n) reported adverse
events
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 9.1.   Comparison 9 Feverfew versus placebo, Outcome 1 Grip strength (mmHg) at 6 weeks.
Study or subgroup Feverfew Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Pattrick 1989 20 110 (49) 20 93 (32) 17[-8.65,42.65]
Favours placebo 10050-100 -50 0 Favours feverfew
 
 
Analysis 9.2.   Comparison 9 Feverfew versus placebo, Outcome 2 Participants (n) reported adverse events.
Study or subgroup Feverfew Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Pattrick 1989 1/20 1/21 1.05[0.07,15.68]
Favours feverfew 200.05 50.2 1 Favours placebo
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Comparison 10.   RA-1 versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from
baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
2 68 tender joint count
change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 66 swollen joint count
change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
4 Modified HAQ (Pune)
change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
5 Patient global (1 to 5)
change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
6 Physician global (1 to 5)
change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
7 ACR20 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
8 ACR50 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 10.1.   Comparison 10 RA-1 versus placebo, Outcome 1 Pain VAS 0-100 change from baseline.
Study or subgroup RA-1 Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Chopra 2000 89 -1.4 (2.6) 93 -1.2 (2.6) -0.19[-0.94,0.56]
Favours RA-1 42-4 -2 0 Favours placebo
 
 
Analysis 10.2.   Comparison 10 RA-1 versus placebo, Outcome 2 68 tender joint count change from baseline.
Study or subgroup RA-1 Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Chopra 2000 89 -13.5 (16.8) 93 -11.6 (17) -1.86[-6.78,3.06]
Favours RA-1 105-10 -5 0 Favours placebo
 
 
Analysis 10.3.   Comparison 10 RA-1 versus placebo, Outcome 3 66 swollen joint count change from baseline.
Study or subgroup RA-1 Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Chopra 2000 89 -9.1 (9.6) 93 -8.2 (9.3) -0.93[-3.68,1.82]
Favours RA-1 105-10 -5 0 Favours placebo
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Analysis 10.4.   Comparison 10 RA-1 versus placebo, Outcome 4 Modified HAQ (Pune) change from baseline.
Study or subgroup RA-1 Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Chopra 2000 89 -3.7 (7.3) 93 -2.7 (5.9) -1.05[-2.98,0.88]
Favours RA-1 42-4 -2 0 Favours placebo
 
 
Analysis 10.5.   Comparison 10 RA-1 versus placebo, Outcome 5 Patient global (1 to 5) change from baseline.
Study or subgroup RA-1 Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Chopra 2000 89 -0.5 (0.9) 93 -0.4 (1) -0.14[-0.42,0.14]
Favours RA-1 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 10.6.   Comparison 10 RA-1 versus placebo, Outcome 6 Physician global (1 to 5) change from baseline.
Study or subgroup RA-1 Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Chopra 2000 89 -0.9 (0.9) 93 -0.7 (1) -0.12[-0.4,0.16]
Favours RA-1 21-2 -1 0 Favours placebo
 
 
Analysis 10.7.   Comparison 10 RA-1 versus placebo, Outcome 7 ACR20 responders.
Study or subgroup RA-1 Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Chopra 2000 39/80 30/85 1.38[0.96,1.99]
Favours placebo 50.2 20.5 1 Favours RA-1
 
 
Analysis 10.8.   Comparison 10 RA-1 versus placebo, Outcome 8 ACR50 responders.
Study or subgroup RA-1 Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Chopra 2000 15/80 5/85 3.19[1.21,8.37]
Favours placebo 100.1 50.2 20.5 1 Favours RA-1
 
 
Comparison 11.   Boswellia serrata versus placebo
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Participants (n) reported adverse events 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 11.1.   Comparison 11 Boswellia serrata versus
placebo, Outcome 1 Participants (n) reported adverse events.
Study or subgroup B serrata Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Sandler 1998 1/18 3/19 0.35[0.04,3.08]
Favours Boswellia serrata 1000.01 100.1 1 Favours placebo
 
 
Comparison 12.   Capsaicin versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 percentage change at 4
weeks
1   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
2 Physician global (-1 to 3) change from
baseline at 4 weeks
1   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
 
 
Analysis 12.1.   Comparison 12 Capsaicin versus placebo, Outcome 1 Pain VAS 0-100 percentage change at 4 weeks.
Study or subgroup Capsaicin Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Deal 1991 14 -57.2 (36.3) 15 -32.2 (37.2) -25[-51.76,1.76]
Favours capsaicin 10050-100 -50 0 Favours placebo
 
 
Analysis 12.2.   Comparison 12 Capsaicin versus placebo, Outcome
2 Physician global (-1 to 3) change from baseline at 4 weeks.
Study or subgroup Capsaicin Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Deal 1991 14 1.4 (1.2) 15 0.1 (1.1) 1.36[0.52,2.2]
Favours placebo 42-4 -2 0 Favours capsaicin
 
 
Comparison 13.   Tripterygium wilfordii (topical) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 42 tender joint count at 6 weeks 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 40 swollen joint count at 6 weeks 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
3 Grip strength (kPa) at 6 weeks 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
4 Morning stiffness (hours) at 6 weeks 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
5 ACR20 responders at 6 weeks 1   Risk Ratio (M-H, Random,
95% CI)
Totals not selected
 
 
Analysis 13.1.   Comparison 13 Tripterygium wilfordii (topical)
versus placebo, Outcome 1 42 tender joint count at 6 weeks.
Study or subgroup T wilfordi topical Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Cibere 2003 31 2.4 (2.4) 30 0.9 (1) 1.5[0.58,2.42]
Favours TW topical 52.5-5 -2.5 0 Favours placebo
 
 
Analysis 13.2.   Comparison 13 Tripterygium wilfordii (topical)
versus placebo, Outcome 2 40 swollen joint count at 6 weeks.
Study or subgroup T wilfordi topical Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Cibere 2003 31 6.3 (3.9) 30 1.9 (2.5) 4.4[2.76,6.04]
Favours TW topical 105-10 -5 0 Favours placebo
 
 
Analysis 13.3.   Comparison 13 Tripterygium wilfordii (topical)
versus placebo, Outcome 3 Grip strength (kPa) at 6 weeks.
Study or subgroup T wilfordi topical Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Cibere 2003 31 52 (35) 30 13 (14) 39[25.7,52.3]
Favours placebo 5025-50 -25 0 Favours TW topical
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Analysis 13.4.   Comparison 13 Tripterygium wilfordii (topical)
versus placebo, Outcome 4 Morning sti>ness (hours) at 6 weeks.
Study or subgroup T wilfordi topical Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Cibere 2003 31 1 (0.6) 30 0.2 (0.4) 0.8[0.54,1.06]
Favours TW topical 21-2 -1 0 Favours placebo
 
 
Analysis 13.5.   Comparison 13 Tripterygium wilfordii (topical)
versus placebo, Outcome 5 ACR20 responders at 6 weeks.
Study or subgroup T wilfordi topical Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Cibere 2003 18/31 6/30 2.9[1.34,6.31]
Favours placebo 100.1 50.2 20.5 1 Favours TW topical
 
 
Comparison 14.   Ganoderma lucidum and SMS versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 ACR20 responders 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Adverse events 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 14.1.   Comparison 14 Ganoderma lucidum and SMS versus placebo, Outcome 1 ACR20 responders.
Study or subgroup G lucidum + SMS Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Li 2007 2/28 4/30 0.54[0.11,2.7]
Favours placebo 1000.01 100.1 1 Favours herbal therapy
 
 
Analysis 14.2.   Comparison 14 Ganoderma lucidum and SMS versus placebo, Outcome 2 Adverse events.
Study or subgroup G lucidum + SMS Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Li 2007 8/22 14/22 0.57[0.3,1.08]
Favours G lucidum+SMS 1000.01 100.1 1 Favours placebo
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Botanical name Plant part Trade-
name
Preparation Drug/Ex-
tract
mg/day Constituent marker Marker
mg/day
References
Populus tremula +
Fraxinus excelsior
+ Solidago virgau-
rea
bark, herb,
leaf
Phytodo-
lor
fresh plant ethanolic (45,6%)
extract
3 : 1 : 1 5-8 ml total flavonoids 0.34-0.56 Eberl 1988;
Meier 1987
Populus tremula bark, leaf   fresh plant ethanolic (45,6%)
extract
    salicin 4.8-8.0  
Solidago virgau-
rea
herb   fresh plant ethanolic (45,6%)
extract
    salicyl alcohol 0.48-0.8  
Fraxinus excelsior bark   fresh plant ethanolic (45,6%)
extract
    isofraxidin 0.67-1.1  
Salix daphnoides bark SM $ ethanolic (70%) extract 8-14:1 1573 salicin 240 Biegert 2004
Tripterygium wil-
fordii Hook F
root SM ethanol / ethyl acetate extract 45:1 180 triptolide 
tripdiolide 
triptonide 
triptophenolide
0.194,
0.056,
0.0142,
0.746
Tao 1995,
Gold-
bach-Mansky
2009
Tripterygium wil-
fordii Hook F
root SM ethanol / ethyl acetate extract 45:1 360 triptolide 
tripdiolide 
triptonide 
triptophenolide
0.389,
0.112,
0.284,
1.472
Tao 1995,
Gold-
bach-Mansky
2009
Tripterygium wil-
fordii Hook F
root T2 chloroform / methanol extract not stated 60 tripdiolide 
triptdiolide 
triptonide 
triptophenolide
0.021,
0.041,
0.002,
0.002
Tao 1995
Tripterygium wil-
fordii (local)
root Thunder
God vine
not stated not stated topical 5-6
times per
day
not stated not stated Cibere 2003
Tripterygium wil-
fordii Hook F
root TwHF ex-
tract
ethanol / ethyl acetate extract not stated 180 triptolide and tripdiolide not stated Gold-
bach-Mansky
2009
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Withania som-
nifera, 
Boswellia serra-
ta, 
Zingiberis offici-
nale, 
Curcuma longa
  RA-1 not stated not stated 444 - 592 not stated not stated Chopra 2000
Clematis mand-
shurica, 
Prunella vulgaris, 
Trichosanthes
kirilowii
root,
flower,
root; 1:1:2
SKI-306X ethanol 30% extracts 
thereafter 
butanol extraction
7:1   oleanolic acid 4%, ros-
marinic acids 0.2%, ursolic
acids 0.5%, hydroxybenzoic
acid 0.03%, 
hydroxymethoxybenzoic
acid 0.03%, trans-cinnamic 
acid 0.05%
  Song 2007
Uncaria tomen-
tosa
bark Krallen-
dorn
aqueous acid axtract not stated 60 pentacyclic 
oxindole alkaloids
0.88 Mur 2002
Tanacetum
parthenium
leaf SM powder   76 parthenolide 2-3 micro-
mol
Pattrick 1989
Capsicum (local) fruit Zostrix not stated 0.025% topical
QID
    Deal 1991
  fruit Arlacel 165 not stated 0.075% topical
QID
    McCarthy
1992
Oenothera bien-
nis
semen SM oil not stated 540 gamma-linolenic acid (GLA) 540 Belch 1988
  semen SM oil 9% GLA 6000 GLA 540 Brzeski 1991
  semen SM oil not stated 20-30 ml GLA not stated Jantti 1989
Ribes nigrum semen SM oil 17% GLA 3000 GLA 525 Watson 1993
  semen SM oil 19% GLA 10500 GLA 2000 Leventhal
1994
Borago officinalis semen SM oil 23% GLA 7.2 ml GLA 1400 Leventhal
1993
Table 1.   Details of the herbal medicinal products used for the treatment of RA  (Continued)
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  semen SM oil 70% GLA   GLA 2800 Zurier 1996
Ganoderma
lucida (4g) +
San Miao San
(Atractylodes
macrocephala
root, Phelloden-
dron chinense
cortex, Achyran-
thes bidentatae
root)
not stated not stated aqueous extract not stated Rhizoma
atracty-
lodis 2.4g;
Cotex
phelloden-
dri 2.4g;
Radix
achyran-
thes
Biden-
tatae 2.4g
not stated not stated Li 2007
    SM = study
medica-
tion
$ ethanolic extract stated in the
thesis (University of Tübingen) 
$ 50g/100 g gel, details from
Bioforce AG/Schweiz
         
Table 1.   Details of the herbal medicinal products used for the treatment of RA  (Continued)
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A P P E N D I C E S
Appendix 1. Search Strategies
MEDLINE
1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$
or artrit$ or diseas$ or condition$ or nodule$)).tw.
3. (felty$ adj2 syndrome).tw.
4. (caplan$ adj2 syndrome).tw.
5. (sjogren$ adj2 syndrome).tw.
6. (sicca adj2 syndrome).tw.
7. still$ disease.tw.
8. bechterew$ disease.tw.
9. or/1-8
10. exp Medicine, Herbal/
11. exp Plants, Medicinal/
12. exp Medicine, Traditional/
13. exp Drugs, Chinese Herbal/
14. herb$.tw.
15. (plant or plants).tw.
16. phytomedicine.tw.
17. botanical.tw.
18. weed$.tw.
19. algae.tw.
20. (fungi or fungus).tw.
21. ((traditional or chinese or herbal) adj medicine).tw.
22. ((oriental or chinese) adj tradition$).tw.
23. or/10-22
24. 9 and 23
EMBASE
1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$
or artrit$ or diseas$ or condition$ or nodule$)).tw.
3. (felty$ adj2 syndrome).tw.
4. (caplan$ adj2 syndrome).tw.
5. (sjogren$ adj2 syndrome).tw.
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6. (sicca adj2 syndrome).tw.
7. still$ disease.tw.
8. bechterew$ disease.tw.
9. or/1-8
10. exp Herbal Medicine/
11. exp Medicinal Plant/
12. exp Traditional Medicine/
13. exp Chinese Medicine/
14. herb$.tw.
15. (plant or plants).tw.
16. phytomedicine.tw.
17. botanical.tw.
18. weed$.tw.
19. algae.tw.
20. (fungi or fungus).tw.
21. ((traditional or chinese or herbal) adj medicine).tw.
22. ((oriental or chinese) adj tradition$).tw.
23. or/10-22
24. 9 and 23
The Cochrane Library (Wiley InterScience)
#1      MeSH descriptor Arthritis, Rheumatoid explode all trees
#2      ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*) near/3 (arthrit*
or artrit* or diseas* or condition* or nodule*)):ti,ab
#3      felty* NEAR/2 syndrome:ti,ab
#4      caplan* NEAR/2 syndrome:ti,ab
#5      sjogren* near/2 syndrome:ti,ab
#6      sicca near/2 syndrome:ti,ab
#7      still* next disease:ti,ab
#8      (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9      MeSH descriptor Medicine, Herbal explode all trees
#10    MeSH descriptor Plants, Medicinal explode all trees
#11    MeSH descriptor Medicine, Traditional explode all trees
#12    MeSH descriptor Drugs, Chinese Herbal explode all trees
#13    herb*:ti,ab
#14    (plant or plants):ti,ab
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#15    phytomedicine:ti,ab
#16    botanical:ti,ab
#17    weed*:ti,ab
#18    algae:ti,ab
#19    algae:ti,ab
#20    (fungi or fungus):ti,ab
#21    ((traditional or chinese or herbal) next medicine):ti,ab
#22    ((oriental or chinese) next tradition*):ti,ab
#23    (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)
#24    (#8 AND #23)
CINAHL (Ovid) (to November 2008)
1     exp Arthritis, Rheumatoid/
2     ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit
$ or artrit$ or diseas$ or condition$ or nodule$)).tw.
3     (felty$ adj2 syndrome).tw.
4     (caplan$ adj2 syndrome).tw.
5     (sjogren$ adj2 syndrome).tw.
6     (sicca adj2 syndrome).tw.
7     still$ disease.tw.
8     bechterew$ disease.tw.
9     or/1-8
10     exp Medicine, Herbal/
11     exp Plants, Medicinal/
12     Medicine, Traditional/
13     exp Plant Extracts/
14     herb$.tw.
15     (plant or plants).tw.
16     phytomedicine.tw.
17     botanical.tw.
18     weed$.tw.
19     algae.tw.
20     (fungi or fungus).tw.
21     ((traditional or chinese or herbal) adj medicine).tw.
22     ((oriental or chinese) adj tradition$).tw.
23     or/10-22
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24     9 and 23
CINAHL (EBSCOhost) (to May 2009)
S16 S14 and S15
S15 S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13
S14 S1 or S2
S13 TI traditional medicine or AB traditional medicine or TI chinese medicine or AB chinese medicine or TI herbal medicine or AB herbal
medicine or TI oriental tradition* or AB oriental tradition* or TI chinese tradition* or AB chinese tradition*
S12 TI ( fungi or fungus ) or AB ( fungi or fungus )
S11 TI algae or AB algae
S10 TI weed* or AB weed*
S9 TI botanical or AB botanical Search
S8 TI phytomedicine or AB phytomedicine
S7 TI ( plant or plants ) or AB ( plant or plants )
S6 TI herb* or AB herb*
S5 (MH "Plant Extracts+")
S4 (MH "Medicine, Traditional+")
S3 (MH "Plants, Medicinal+")
S2 TI "bechterew* disease" or AB "bechterew* disease" or TI (arthritis N2 rheumat*) or AB (arthritis N2 rheumat*)
S1 (MH "Arthritis, Rheumatoid+") or TI ( felty* N2 syndrome) or AB (felty* N2 syndrome) or TI (caplan* N2 syndrome) or AB (caplan* N2
syndrome) or TI (rheumatoid nodule) or AB (rheumatoid nodule) or TI (sjogren* N2 syndrome) or AB (sjogren* N2 syndrome) or TI (sicca
N2 syndrome) or AB (sicca N2 syndrome)
AMED
1     exp Arthritis rheumatoid/
2     ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit
$ or artrit$ or diseas$ or condition$ or nodule$)).tw.
3     (felty$ adj2 syndrome).tw.
4     (caplan$ adj2 syndrome).tw.
5     (sjogren$ adj2 syndrome).tw.
6     (sicca adj2 syndrome).tw.
7     still$ disease.tw.
8     bechterew$ disease.tw.
9     or/1-8
10     exp herbal drugs/
11     exp traditional medicine/
12     exp plant extracts/
13     exp plants medicinal/
14     herb$.tw.
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15     (plant or plants).tw.
16     phytomedicine.tw.
17     botanical.tw.
18     weed$.tw.
19     algae.tw.
20     (fungi or fungus).tw.
21     ((traditional or chinese or herbal) adj medicine).tw.
22     ((oriental or chinese) adj tradition$).tw.
23     or/10-22
24     9 and 23
Web of Science
#1 Topic=(((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*) and
(arthrit* or artrit* or diseas* or condition* or nodule*))) OR Topic=((felty* or caplan* or sjogren* or sicca* or still*) and (disease or syn-
drome))
#2 Topic=(herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus)
#3 Topic=((oriental or chinese or traditional) and (medicine or therap*))
#4 #3 OR #2
#5 #4 AND #1
Dissertation Abstracts
Citation and abstract = rheum* or arthrit* or felty* or caplan* or sjogren* or sicca* or still*
AND
Citation and abstract = herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus oriental or chinese
or traditional
AND
Citation and abstract = medicin* or therap*
W H A T ' S   N E W
 
Date Event Description
14 July 2010 New citation required and conclusions
have changed
New authors completed the update; substantial changes were
made, including incorporating updated Cochrane methods in
searching for studies; assessing risk of bias; and collating sum-
mary of findings table to help interpretation of results. Inclusion
criteria were expanded such that language of publication was
no longer a barrier to inclusion, studies using active as well as
placebo controls were included, and unpublished reports of ran-
domised controlled trials were eligible for inclusion.
27 October 2009 New search has been performed Search updated to 2009, unrestricted by language. To identify
studies inadvertently omitted from the original review, we re-
peated the search strategy from 1966 to 1999. We added three
additional trials to an update published in a peer review journal.
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Date Event Description
This amounted to a total of 12 new trials being added in this up-
date compared to the last published Cochrane review.
30 April 2008 Amended Converted to new review format. CMSG ID A009-R
 
C O N T R I B U T I O N S   O F   A U T H O R S
Christine Little, Tessa Parsons, Melainie Cameron, Sigrun Chrubasik, and Joel Gagnier selected literature. Melainie Cameron, Sigrun
Chrubasik, Tessa Parsons, Anette Bluemle, and Joel Gagnier extracted data from some studies. Melainie Cameron conducted the pooled
data analyses. All authors wrote the updated review, then checked, proof-read and approved the updated review.
D E C L A R A T I O N S   O F   I N T E R E S T
None known.
S O U R C E S   O F   S U P P O R T
Internal sources• Victoria University, Australia.• University of Freiburg, Germany.
External sources• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
For this review update, we expanded inclusion criteria so studies that included an active control as well as placebo controls, randomised
controlled trials published in any language, and unpublished reports of randomised controlled trials were eligible for inclusion. Changes
to methods of quality assessment (replaced by assessment of 'risk of bias') and analysis and presentation of results are consistent with
updated Cochrane Collaboration and Cochrane Musculoskeletal Group methods introduced since the original review.
One study included in the original review recruited participants with any form of arthritic disease (Mills 1996). This study was excluded
from this update because data for the subgroup of participants with rheumatoid arthritis could not be distinguished from the overall
data reported. In the original review, studies of the same herbal therapy that used the same outcome measure were pooled regardless
of the length of the intervention period. In this update, these data and comparisons have been subgrouped according to intervention
time, rather than pooled. The table of herbal interventions has been extensively revised so that it offers detailed information about the
herbal medicines, including full botanical names, the part of the plant used, details of extraction methods, drug:extract ratios and co-
active principles. Three further tables have been added; two cover current understandings of the mechanisms of action of herbal therapies
and the other table summarises the clinical implications arising from this review.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Phytotherapy;  Antirheumatic Agents  [*therapeutic use];  Arthritis, Rheumatoid  [*drug therapy];  Placebo E@ect;  Plant Oils  [*therapeutic
use];  Primula;  Randomized Controlled Trials as Topic;  Tripterygium;  gamma-Linolenic Acid  [*therapeutic use]
MeSH check words
Humans
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